



PATENT #16
Docket No.: CLV-30880/A/CGV2112

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Martha Martin
Type or print name

Martha Martin
Signature

June 19, 2008
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Hirt, et al

APPLICATION NO: 09/525,158

FILED: March 14, 2000

FOR: Organic Compounds

Examiner:

Kuo-Liang Peng

Art Unit: 1712

RECEIVED

JUN 30 2008

OFFICE OF PETITIONS

Attention: Office of Petitions
Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
FAX (571) 273-8300

Adjustment date: 11/12/2008 CKHLOK
06/26/2008 TL0011 00000001 502965 09525158
01 FC:1453 1540.00 CR

RENEWED PETITION UNDER 37 C.F.R. §1.137(b) AND/OR
RENEWED PETITION TO WITHDRAW THE HOLDING OF ABANDONMENT

Dear Sir:

This is a renewed petition to revive the subject application.

The Decision on Petition on February 20, 2008 from the Office of Petitions dismissed Applicants' petitions to withdraw holding of abandonment and petition under 37 C.F.R. §1.137(b). In response to the dismissal decision, Applicants respectfully request reconsideration of the Applicants' petition in view the Applicants' arguments *infra* and the attached documents supporting the Applicants' arguments. The documents submitted herewith include, copies of four work dockets (redacted) for Jian Zhou and printed on May 1, 2002, August 28, 2002, November 20, 2002, and August 14, 2006 respectively (Appendices A1-A4), Case Docket Report printed out on April 16, 2008 (Appendix B), the copy of the case folder showing all of entries in this case (Appendix C), copies of the redacted minutes of IPSC

06/26/2008 TL0011 00000001 502965 09525158

01 FC:1453 1540.00 DA

(Intellectual Property Steering Committee) meetings mentioning this case CLV-30880 from 1999 to 2007 (Appendices D1-D13), copies of CLV-30880 docket records incorporated in IPSC Booklets (Appendices E1-E5), and copies of all of the internal communications found in the case folder (Appendices F1-F20).

PETITION TO WITHDRAW HOLDING OF ABANDONMENT

The Office of Petitions dismissed the Applicants' petition to withdraw holding of abandonment, because no status inquiries were filed during the period from the filing of the original petition to withdraw the holding of abandonment on May 28, 2002 to the filing of the subject petition on September 11, 2007. Applicants respectfully submit that the dismissal is improper because of lack of justification for dismissal for the following reasons.

It is true that MPEP 203.08 states, in pertinent part, that "in the event that a six month period has elapsed, and no response from the Office is received, applicant should inquire as to the status of the application to avoid potential abandonment." (cited by the Petition Office; emphasis in the original) However, the examination of the language in MPEP 203.08 cited by the Petition Office reveals that MPEP 203.08 does not, at all, absolutely mandate/command the applicant to inquire as to the status of the application, because MPEP 203.08 uses the word "should", not "shall" or "must", in the language. Instead, MPEP 203.08 merely recommends or encourages applicants to make status inquiries. Moreover, MPEP 203.08 states, "Applicants are encouraged to use PAIR to make status inquiries" (the sentence following immediately the sentence cited by the Petition Office) [Emphasis added]. This sentence clearly indicates that lack of status inquiry would not constitute a basis for rejecting a timely-filed petition to withdraw holding of abandonment, because status inquiries made on PAIR cannot make evidentiary records and cannot induce the Patent Office to act on the petition. Therefore, without commanding word "shall" or "must", there is no basis to dismiss the applicants' petition so long as the applicants' original petition was timely filed and met the requirements when it was filed.

Applicants respectfully request reconsideration the petition to withdraw holding of abandonment. Alternatively, Applicants request reconsideration of the petition under 37 C.F.R. §1.137(b) for the reasons stated below.

PETITION UNDER 37 CFR §1.137(b)

The Office of Petitions dismissed the Applicants' petition under 37 C.F.R. §1.137(b), because the petition filed on September 14, 2007 lacks a statement that the entire delay in

filing the required reply from the due date for the replay until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional (Decision, page 4, 6th full paragraph, last sentence). In response, Applicants respectfully request reconsideration in view of the arguments below and documents attached herewith.

First, the entire delay in filing the required reply from the due date for the replay until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional.

As stated in the petition to withdraw holding of abandonment, Applicants' representative did not receive the Notice of Allowance and the entire delay in paying the required issue fee within the statutory period of three months from the mailing date of the Notice of Allowance was unintentional. The failure to pay the issue fee was discovered on April 25, 2002, when Applicants received the Notice of Abandonment dated April 5, 2002. After having received the Notice of Abandonment dated April 5, 2002, Applicants timely filed the Petition to Withdraw Holding of Abandonment pursuant to 37 C.F.R. §1.181(a), copy of which is attached herewith along with the Return-Receipt Post Card with USPTO stamp of date of May 28, 2002 as well as the petition's supporting documents (a copy (2 pages) of the docket record showing all received Office Actions and replies filed by Applicants' representative; email communication concerning non-receipt of the Notice of Allowance; and a statement of non-receipt of the Notice of Allowance from Jian Zhou, Applicants' representative).

Inadvertently and erroneously, the event of filing Petition to Withdraw Holding of Abandonment was docketed in the database as an event of filing Response to Office Action in the docket for this case (see Appendix B attached herewith, though the entry for this event was correct on the case folder (see the attached Appendix C). Because of this docketing error, the event "status check" did not appear in action dockets to prompt the Applicants' representative to inquire as to the status of the petition since May 10, 2002 (see Appendices A1-A4). Appendix A1 (the action docket prior to filing of petition to withdraw holding of abandonment on May 25, 2002) shows that there was response due for the Applicant's representative on page 77. Appendices A2-A4 show that no action was due for this case in action dockets after the petition to withdraw holding of abandonment was filed on May 25, 2002.

Applicants did not have any intention to abandon this application, but instead, did intend to maintain patents/patent applications for this case in the U.S. and other foreign countries, as supported by the documents attached herewith (Appendices D1-D13 and E1-E5). The copies of the redacted minutes of IPSC (Intellectual Property Steering Committee)

meeting discussing cases including this pending application (Appendices D1-D13) show that since having filed this patent application March 30, 1999, Applicants never wanted to abandon the patent application in the U.S., but instead always decided to maintain the patent application in the U.S. The docket records for this case were incorporated in the IPSC Booklets and the copies thereof (Appendices E1-E5) show that the status of the U.S. patent application for this case was pending.

Applicants did not deliberately choose not to seek or persist in seeking the revival of an abandoned application. As discussed above, Applicants timely filed a petition to withdraw holding of abandonment with all necessary support documents, within one month after Applicants discovered the failure to pay issue fee. The Patent Office acknowledged the receipt of that petition and supporting documents by mailing back to Applicants the Return-Receipt Post Card with US PTO stamp of date of May 28, 2002. The Patent Office further conceded in the Decision on Petition that Applicants did timely file a petition with the documents supporting the petition, because the Patent Office did locate them in the official file. The filing of Applicants' petition to withdraw holding of abandonment was a *bona fide* attempt to revive the application, because the petition was filed timely and met the requirements set forth in MPEP 711.03(c)(I), Subsection A. The petition itself is the best evidence showing the Applicants' intent to revive the patent application. Applicants did not do anything causing the Patent Office not to consider the Applicants' petition during a period of five years. What Applicants failed to do was at most the failure to inquire as to the status of the petition. Such failure was due to the inadvertent docketing error discussed above. However, as discussed above, lack of status inquiry could not constitute any basis for rejecting a timely-filed petition to withdraw holding of abandonment. The inadvertent error in docketing and subsequent failure to inquire as to the status of a timely-filed bona fide petition to withdraw holding of abandonment clearly do not constitute any deliberate action taken by Applicants not to seek or persist in seeking the revival of an abandoned application.

Applicants submit herewith the copies (Appendices F1-F20) of the internal communications which are located in the CL/V-30880A case folder. None of the communications can show that Applicants deliberately choose not to seek or persist in seeking the revival of an abandoned application.

In the Q2 2007 IPSC meeting, this case was reviewed again along with many other cases. Applicants' representatives realized that the subject application was pending for too long. Subsequent review of the case folder revealed that Applicants filed a petition to withdraw holding of abandonment on May 10, 2002, but had not received any decision. Applicants

decided to submit the petition to revive the subject application in accordance with 37 C.F.R. §1.137(b), in order to expedite the petition process and issuance of the subject application. On September 11, 2007, Applicants filed the petition which was dismissed by the Petition Office on February 20, 2008.

Therefore, when considering all of the circumstances surrounding the subject application, the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional.

Second, the facts here are materially distinguishable from the facts in each of the case law authorities cited by the Petition Office to support its decision to dismiss the Applicants' petition to revive the subject application in accordance with 37 C.F.R. §1.137(b) as follows.

In *Lawman Armor v. Simon*, 2005 U.S. Dist. LEXIS 10843, 74 U.S.P.Q.2d 1633 (E. D. Mich. 2005), the court found that the defendant had made a decision not to pursue the prosecution of his patent application, because the defendant failed to respond to his representative's two requests for instruction regarding filing a response to final Office Action and to pay his representative's service rendered for prosecuting his patent application, and because the defendant "regained interest in his by then abandoned patent application" after about two years when he discovered the allegedly infringing product at Sears. The court ruled that "these were deliberate acts, and cannot be considered unintentional." In contrast to the defendant in the *Lawman* case, Applicants here did not take deliberate acts not to respond to an office action, but instead took affirmative and timely action to seek to respond to an office action by requesting a Notice of Allowance be remailed in the timely-filed petition to withdraw holding of abandonment. Applicants here timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee. Here, there was no purposeful delay in seeking revival, unlike in the *Lawman* case.

In *Field Hybrids, LLC v. Toyota Motor Corp.*, 2005 U.S. Dist. LEXIS 1159 (D. Minn. 2005), although the plaintiff knew that his patent application was in danger of being abandoned through his representatives' communications to him, he explicitly requested his representative to "proceed no further with [his patent application] at this point." In contrast to the plaintiff in the *Field Hybrids* case, Applicants here took affirmative and timely action to seek to respond to an office action by requesting a Notice of Allowance be re-mailed in the timely-filed petition to withdraw holding of abandonment. Applicants here timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of

abandonment after discovering the failure to pay the issue fee. Here, there was no purposeful decision to take no action, unlike in the Field Hybrids case.

In *Lumenyte Int'l Corp. v. Cable Lite Corp.*, Nos. 96-1011, 96-1077, 1996 U.S. App. LEXIS 16400, 1996 WL 383927 (Fed. Cir. 1996), in a letter to Mr. Willford (the president of the plaintiff), Mr. Rozsa (the plaintiff's representative) summarized a prior conversation and stated that "[Mr. Willford] informed me that [he has] decided not to spend additional money prosecuting the above referenced patent application and that it was [his] desire not to respond to the outstanding office action of February 4, 1988. Therefore, I will not do any further work on this application and it will go abandoned on August 4, 1988." Based on this evidence and others in the records, the Lumenyte court found that the plaintiff intentionally abandoned its patent application and was revived only after and because Fiber Lite ("former name of Cable Lite") introduced a competing product. In contrast to the plaintiff in the Lumenyte case, Applicants here never intentionally abandoned the subject patent application, but instead, timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee.

In *New York University v. Autodesk*, 2007 U.S. Dist. LEXIS 50832 (S.D.N.Y. 2007), the key facts were: (1) the PTO's records (Examiner Burwell's note) showed that the PTO examiner telephoned NYU's then attorney who confirmed the abandonment; and (2) several months later NYU's new attorney filed a petition to revive the application under 37 C.F.R. §1.137(b) and did not provide any reason or support for the representation that NYU's failure to file a response was unintentional. The court there held that "[i]n light of [examiner Burwell's note], without more, no reasonable factfinder could find that NYU's decision not to take action – and instead to 'delay' seeking revival – for the entire period between July 14, 1997 and November 4, 1998 was 'inintentional' under 37 C.F.R. §1.137(b)(3)." In contrast to the NYU v. Autodesk case, Applicants here did not decide not to take action, but instead timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee.

Applicants respectfully submit that, because the facts here are materially distinguishable from the facts in each of the case law authorities cited by the Petition of Office to support its decision to dismiss the Applicants' petition to revive the subject application in accordance with 37 C.F.R. §1.137(b), the cited case law is inapplicable to the pending petition.

Applicants hereby request two months of extension of time under 37 C.F.R. §1.136(a) and authorize payment of the extension of time fee of \$460 under 37 C.F.R. §1.17(a)(2) and other necessary fees by debit of their Deposit Account No. 50-2965 in accordance with 37 C.F.R. §1.17(m).


Applicants hereby authorize payment of the issue fee by debit of their Deposit Account 50-2965 without the issue fee authorization form PTOL 85 B, because Applicants have not received the Notice of Allowance and this form. Alternatively, Applicants respectfully request that a new Notice of Allowance with Form PTOL 85B be re-issued so that Applicant can pay the issue fee.

Since this application was filed on or after June 8, 1995, no terminal disclaimer is required.

Applicants respectfully request that this Petition to revive be granted.

Should the Examiner and/or Senior Petitions Attorney believe that a discussion with Applicants' representative would further the prosecution of this application, either is respectfully invited to contact the undersigned. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 50-2965.

Respectfully submitted,



Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date: June 19, 2008

CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097-1556

May 8, 2002

(A1)

DOCKET MANAGEMENT SYSTEM

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

~~CONFIDENTIAL~~
copy
Jian's

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/292,980	D C		CVC	JZ			
		60/292,971	D C		CVC	JZ			
		60/293,026	D C		CVC	JZ			
		60/294,407	D C		CVC	JZ			
		60/294,512	D C		CVC	JZ			
		60/294,396	D C		CVC	JZ			
		60/294,397	I C		CVC	JZ			
		60/301,260	I C		CVC	JZ			
		60/303,632	I C		CVC	JZ			
		60/305,684	I C		CVC	JZ			
		09/609,493	D		CVC	JZ			
		60/292,980	C C		CVC	JZ			
		60/292,971	C		CVC	JZ			

additional selection criteria:

done?

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	APPLICATION			STATUS	EFFECTIVE DATE
						PO ACTION	PO DATE	STATUS		
		60/293,026		CVC	JZ					11
		60/294,407		CVC	JZ					11
		60/294,512		CVC	JZ					1
		60/294,396		CVC	JZ					11
		60/294,397		CVC	JZ					11
		60/313,967		CVC	JZ					11
		60/292,980		CVC	JZ					1
		60/292,971		CVC	JZ					1
		60/293,026		CVC	JZ					
		60/301,260		CVC	JZ					
		60/294,407		CVC	JZ					

additional selection criteria:

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/294,512		CVC	JZ				
		60/294,396		CVC	JZ				
		60/294,397		CVC	JZ				
		60/303,632		CVC	JZ				
		60/305,684		CVC	JZ				
		60/292,980	EED	CVC	JZ				
		60/292,971	EED	CVC	JZ				
		60/293,026	EED	CVC	JZ				
			N	CVC	JZ				
		60/325,133		CVC	JZ				
		60/325,101		CVC	JZ				
		60/301,260		CVC	JZ				

Done

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE

done

09/627,807

60/294,407

60/294,512

60/294,396

60/294,397

60/303,632

10/091,819

09/725,405

60/305,684

60/313,967

60/292,980

60/292,971

done

DOCKET MANAGEMENT SYSTEM

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/293,026		CVC	JZ				
		60/301,260		CVC	JZ				
		60/334,709		CVC	JZ				
		60/294,407		CVC	JZ				
		60/294,512		CVC	JZ				
		60/294,396		CVC	JZ				
		60/294,397		CVC	JZ				
		60/334,854		CVC	JZ				
		10/091,819		CVC	JZ				
		60/303,632		CVC	JZ				
		60/347,995		CVC	JZ				
		60/348,257		CVC	JZ				

additional selection criteria:

7.2

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	APPLICATION			STATUS EFFECTIVE DATE
						PO ACTION	PO DATE	STATUS	
				CVC	JZ				
		60/337,763		CVC	JZ				
		60/340,410		CVC	JZ				
		60/364,192		CVC	JZ				
		60/332,289		CVC	JZ				
		60/305,684		CVC	JZ				
		60/313,967		CVC	JZ				2
		60/292,980		CVC	JZ				1
		60/292,980		CVC	JZ				1
		60/292,971		CVC	JZ				1
		60/292,971		CVC	JZ				1

additional selection criteria:

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	RESPONS.		PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
				ATTORNEY (CASE)	GROUP				
0	A			JZ	CVC				
0	ROV/CVA	60/293,026		JZ	CVC				
0	ROV/CVA	60/325,133		JZ	CVC				
0	ROV/CVA	60/325,101		JZ	CVC				
0	A			JZ	CVC				
0	ROV/CVA	60/301,260		JZ	CVC				
0	1239	09/286,530		JZ	CVC				
0	ROV/CVA	60/294,407		JZ	CVC				
0	ROV/CVA	60/294,407		JZ	CVC				
0	ROV/CVA	60/294,512		JZ	CVC				
0	ROV/CVA	60/294,512		JZ	CVC				
0	ROV/CVA	60/294,396		JZ	CVC				
0	ROV/CVA	60/294,396		JZ	CVC				

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
	A	60/294,397		CVC	JZ				
	A	60/294,397		CVC	JZ				
		09/331,516		CVC	JZ				
06/05/2002	CL/V -30880/A/CGV 2112	09/525,158	RESPONSE	CVC	JZ	NOTICE OF ABANDONMENT	04/05/2002	PENDING	03/14/2000
		60/303,632		CVC	JZ				
		10/091,819		CVC	JZ				
		60/340,806		CVC	JZ				
		60/340,410		CVC	JZ				
		09/558,135		CVC	JZ				
		60/305,684		CVC	JZ				
		60/313,967		CVC	JZ				
		09/367,274		CVC	JZ				
		09/438,684		CVC	JZ				

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	RESPONS.		ATTORNEY ACTION DUE	GROUP	ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
	A	60/325,133				CVC	JZ				
	A	60/325,101				CVC	JZ				
	A	60/301,260				E CVC	JZ				
	A	60/301,260				CVC	JZ				
	A	60/334,709				CVC	JZ				
	A	60/334,854				CVC	JZ				
		09/331,516				CVC	JZ				
		60/303,632				3 CVC	JZ				
		60/303,632				CVC	JZ				
		60/347,995				CVC	JZ				
		60/348,257				CVC	JZ				
		60/337,763				CVC	JZ				
		60/347,116				CVC	JZ				

additional selection criteria:

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/332,289	CK CC						
		60/305,684	DE XJ	E CVC	JZ				
		60/305,684	FJ AJ	CVC	JZ				
		60/313,967	RJ	CVC	JZ				
		09/367,274	I	CVC	JZ				
		60/325,133	I N	CVC	JZ				
		60/325,101	I N	CVC	JZ				
		60/334,709	I	CVC	JZ				
		60/334,854	I	CVC	JZ				
		60/347,995	I	CVC	JZ				
		60/348,257		CVC	JZ				
		60/337,763		CVC	JZ				
		60/340,806		CVC	JZ				

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	APPLICATION			STATUS	EFFECTIVE DATE
						PO ACTION	PO DATE	STATUS		

CONVERT?

VA	60/332,289	I		CVC	JZ					
VA	60/340,410	(CVC	JZ					
VA	60/313,967	I	I-E	CVC	JZ					
VA	60/313,967	I		CVC	JZ					
VA	60/325,133	I	SE	CVC	JZ					
VA	60/325,101	I	SE	CVC	JZ					
VA	60/334,709	:	SED	CVC	JZ					
VA	60/334,854	:	EED	CVC	JZ					

additional selection criteria:

Through: 11/30/2002

Printed: 08/28/2002

A2

ATTORNEY #1 DOCKET FOR JIAN ZHOU

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	AVAILABLE
DUE	PARA						EXT			
September 1998										
24 Thu	JZ/RJG/RIG			RE CIBA Vision Corporation	(US)	N/A	0			None
March 1999										
24 Wed	JZ/RJG/RIG			RE CIBA Vision Corporation	(US)	N/A	0			None
November 2000										
12 Sun	JZ/RJG/RIG			CIBA Vision Corporation	(US)	10/197,036	0			None
January 2001										
09 Tue	JZ/RJG/RIG			3 C CIBA Vision Corporation	(US)	09/710,514	0			None
March 2001										
22 Thu	JZ/RJG/RIG			MA CIBA Vision Corporation	(US)	09/766,725	0			None
April 2001										
15 Sun	JZ/RJG/RIG			CIBA Vision Corporation	(US)	09/784,471	0			None
May 2001										
05 Sat	JZ/RJG/RIG			IN CIBA Vision Corporation	(US)					None
16 Wed	JZ/RJG/RIG			ITA CIBA Vision Corporation	(US)	09/811,023				None
19 Sat	JZ/RJG/RIG			CIBA Vision Corporation	(US)	09/444,480				None
June 2001										
25 Mon	JZ/RJG/RIG			L CIBA Vision Corporation	(US)	09/775,104				None
July 2001										
16 Mon	JZ/RJG/RIG			CIBA Vision Corporation	(US)	09/858,394				None

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT
DUE	PARA						EXT	AVAILABLE	
August 2001									
04 Sat	JZ/RJG/RIG				(US) 09/873,827				
12 Sun	JZ/RJG/RIG				(US) 09/879,013				
September 2001									
06 Thu	JZ/RJG/RIG				(US) 09/901,886				
23 Sun	JZ/RJG/RIG				(US) 09/911,221				
23 Sun	JZ/RJG/RIG				(US) 09/911,330				
23 Sun	JZ/RJG/RIG				(US) 09/911,332				
23 Sun	JZ/RJG/RIG				(US) 09/911,218				
October 2001									
02 Tue	JZ/RJG/RIG				(US) 09/920,690				
14 Sun	JZ/RJG/RIG				(US) 09/929,396				
24 Wed	JZ/RJG/RIG				(US) 09/939,145				
29 Mon	JZ/RJG/RIG				(US) 09/941,818				
November 2001									
02 Fri	JZ/RJG/RIG				(US) 09/442,397				
January 2002									
16 Wed	JZ/RJG/RIG				(US) 09/981,391				
18 Fri	JZ/RJG/RIG				(US) 09/559,945				
22 Tue	JZ/RJG/RIG				(US) 10/047,042				
February 2002									

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
February continued...										
04 Mon	JZ/RJG/RIG				(US) 09/755,443					
March 2002										
20 Wed	JZ/RJG/RIG				(US) 10/019,134					
April 2002										
04 Thu	JZ/RJG/RIG				(US) 09/873,827					
24 Wed	JZ/RJG/RIG				(US) 10/056,694					
24 Wed	JZ/RJG/RIG				(US) 10/056,168					
June 2002										
06 Thu	JZ/RJG/RIG				(US) 10/091,819					
13 Thu	JZ/RJG/RIG				(US) 09/698,544					
26 Wed	JZ/RJG/RIG				(US) 09/893,148					
July 2002										
03 Wed	JZ/RJG/RIG				(US) 10/115,401					
14 Sun	JZ/RJG/RIG				(US) 60/332,289					
21 Sun	JZ/RJG/RIG				(US) 60/313,898					
22 Mon	JZ/RJG/RIG				(US) 10/127,736					
29 Mon	JZ/RJG/RIG				(US) 10/106,739					
29 Mon	JZ/RJG/RIG				(US) 09/879,013					
31 Wed	JZ/RJG/RIG				(US) 09/774,942					

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT
DUE	PARA						EXT	AVAILABLE	
August 2002									
07 Wed	JZ/RJG/RIG				(US) N/A				
09 Fri	JZ/RJG/RIG				(US) 10/141,746				
09 Fri	JZ/RJG/RIG				(US) 10/142,300				
09 Fri	JZ/RJG/RIG				(US) 60/371,561				
14 Wed	JZ/RJG/RIG				(US) 60/332,289				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
22 Thu	JZ/RJG/RIG				(US) 10/153,047				
22 Thu	JZ/RJG/RIG				(US) 10/152,941				
22 Thu	JZ/RJG/RIG				(US) 10/153,037				
22 Thu	JZ/RJG/RIG				(US) 10/154,249				
22 Thu	JZ/RJG/RIG				(US) 10/153,040				
22 Thu	JZ/RJG/RIG				(US) 10/153,007				
22 Thu	JZ/RJG/RIG				(US) 10/153,063				
24 Sat	JZ/RJG/RIG				(US) 09/939,145				
26 Mon	JZ/RJG/RIG				(US) 09/893,148				
September 2002									
05 Thu	JZ/RJG/RIG				(US) 10/154,249				

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT		
DUE	PARA						EXT	AVAILABLE			
September continued...											
06 Fri	JZ/RJG/RIG				(US) 09/559,945					e	
07 Sat	JZ/RJG/RIG				(US) N/A					e	
11 Wed	JZ/RJG/RIG				(US) 09/755,357					h	
14 Sat	JZ/RJG/RIG				(US) 60/332,289					e	
15 Sun	JZ/RJG/RIG				(US) 08/274,942					e	
16 Mon	JZ/RJG/RIG				(US) 09/811,023					e	
19 Thu	JZ/RJG/RIG				(US) 10/153,007					h	
20 Fri	JZ/RJG/RIG				(US) 09/508,785					e	
20 Fri	JZ/RJG/RIG				(US) 10/175,656					e	
20 Fri	JZ/RJG/RIG				(US) 09/725,405					e	
21 Sat	JZ/RJG/RIG				(US) 09/714,691					e	
21 Sat	JZ/RJG/RIG				(US) N/A					e	
26 Thu	JZ/RJG/RIG				(US) 08/274,942					e	
27 Fri	JZ/RJG/RIG				(US) 10/153,063					h	
October 2002											
02 Wed	JZ/RJG/RIG				(US) 09/530,073					h	
03 Thu	JZ/RJG/RIG				(US) 10/190,415					e	
03 Thu	JZ/RJG/RIG				(US) 09/784,471					h	
04 Fri	JZ/RJG/RIG				(US) 09/939,145					e	

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2 DUE PARA		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
October continued...								
07 Mon	JZ/RJG/RIG				(US) N/A			e
08 Tue	JZ/RJG/RIG				(US) 10/091,820			e
09 Wed	JZ/RJG/RIG				(US) 10/191,613			e
12 Sat	JZ/RJG/RIG				(US) 10/191,613			h
14 Mon	JZ/RJG/RIG				(US) 60/332,289			e
19 Sat	JZ/RJG/RIG				(US) 09/838,439			e
23 Wed	JZ/RJG/RIG				(US) 09/586,859			e
23 Wed	JZ/RJG/RIG				(US) 09/438,684			e
31 Thu	JZ/RJG/RIG				(US) N/A			e
November 2002								
02 Sat	JZ/RJG/RIG				(US) 09/409,759			e
07 Thu	JZ/RJG/RIG				(US) 60/347,995			e
07 Thu	JZ/RJG/RIG				(US) 60/347,995			e
07 Thu	JZ/RJG/RIG				(US) 60/347,995			e
07 Thu	JZ/RJG/RIG				(US) 60/347,995			e
07 Thu	JZ/RJG/RIG				(US) N/A			e
07 Thu	JZ/RJG/RIG				(US) N/A			e
07 Thu	JZ/RJG/RIG				(US) N/A			e

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	AVAILABLE
DUE	PARA						EXT	EXT	AVAILABLE
November continued...									
07 Thu	JZ/RJG/RIG				(US) N/A	C			
07 Thu	JZ/RJG/RIG				(US) N/A	F			
07 Thu	JZ/RJG/RIG				(US) N/A	F			
07 Thu	JZ/RJG/RIG				(US) N/A	I			
12 Tue	JZ/RJG/RIG				(US) 09/645,900	F			
14 Thu	JZ/RJG/RIG				(US) 09/811,023	I			
14 Thu	JZ/RJG/RIG				(US) 60/332,289	F			
14 Thu	JZ/RJG/RIG				(US) 60/332,289	F			
14 Thu	JZ/RJG/RIG				(US) 60/332,289	I			
16 Sat	JZ/RJG/RIG				(US) 09/858,394	I			
21 Thu	JZ/RJG/RIG				(US) N/A	I			
30 Sat	JZ/RJG/RIG				(US) 09/867,827	I			
CALL-UP DATE:									
December 2002									
04 Wed	JZ/RJG/RIG				(US) 09/873,827	I			
02 Thu	JZ/RJG/RIG				(US) 09/879,013	I			
04 Sat	JZ/RJG/RIG				(US) 60/340,410				
04 Sat	JZ/RJG/RIG				(US) 60/340,410				
00 Fri	JZ/RJG/RIG				(US) 10/019,134				

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	AVAILABLE
DUE	PARA						EXT	AVAILABLE	
December continued...									
26 Thu	JZ/RJG/RIG				(US) 09/893,148	I			one
26 Thu	JZ/RJG/RIG				(US) 09/893,148	I			one
January 2003									
09 Thu	JZ/RJG/RIG				(US) 60/347,116	F			one
09 Thu	JZ/RJG/RIG				(US) 60/347,116	F			one
24 Fri	JZ/RJG/RIG				(US) 10/056,694	F			one
24 Fri	JZ/RJG/RIG				(US) 10/056,168	F			one
February 2003									
14 Fri	JZ/RJG/RIG				(US) 60/356,954	F			re
14 Fri	JZ/RJG/RIG				(US) 60/356,954	F			re

Best Available Copy

A3

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	AVAILABLE
DUE	PARA						EXT	AVAILABLE	
September 1998									
24 Thu	JZ/RJG/RIG				(US) 10/225,062	F			ne
March 1999									
24 Wed	JZ/RJG/RIG				(US) 10/225,062	P			ne
November 2000									
12 Sun	JZ/RJG/RIG				(US) 10/197,036	F			ne
January 2001									
09 Tue	JZ/RJG/RIG				(US) 09/710,514	P			ne
March 2001									
07 Wed	JZ/RJG/RIG				(US) 09/731,331	IF			ne
22 Thu	JZ/RJG/RIG				(US) 09/766,725	P			ne
April 2001									
15 Sun	JZ/RJG/RIG				(US) 09/784,471	P			ne
16 Mon	JZ/RJG/RIG				(US) 09/811,023	R			ne
May 2001									
15 Sat	JZ/RJG/RIG				(US)	F			re
16 Wed	JZ/RJG/RIG				(US) 09/811,023	P			re
19 Sat	JZ/RJG/RIG				(US) 09/444,480	S			re
20 Sun	JZ/RJG/RIG				(US) 6,440,411	R			re
July 2001									

Best Available Copy

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
July continued...										
16 Mon	JZ/RJG/RIG				(US) 09/858,394					
August 2001										
02 Thu	JZ/RJG/RIG				(US) 09/920,690					
04 Sat	JZ/RJG/RIG				(US) 09/873,827					
12 Sun	JZ/RJG/RIG				(US) 09/879,013					
September 2001										
06 Thu	JZ/RJG/RIG				(US) 09/901,886					
10 Mon	JZ/RJG/RIG				(US) 09/920,690					
23 Sun	JZ/RJG/RIG				(US) 09/911,221					
23 Sun	JZ/RJG/RIG				(US) 09/911,330					
23 Sun	JZ/RJG/RIG				(US) 09/911,332					
23 Sun	JZ/RJG/RIG				(US) 09/911,218					
October 2001										
02 Tue	JZ/RJG/RIG				(US) 09/920,690					
14 Sun	JZ/RJG/RIG				(US) 09/929,396					
24 Wed	JZ/RJG/RIG				(US) 09/939,145					
29 Mon	JZ/RJG/RIG				(US) 09/941,818					
December 2001										
07 Fri	JZ/RJG/RIG				(US) 09/731,331					
January 2002										

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
January continued...										
16 Wed	JZ/RJG/RIG				(US) 09/981,391					
February 2002										
04 Mon	JZ/RJG/RIG				(US) 09/755,443					
07 Thu	JZ/RJG/RIG				(US) 09/731,331					
March 2002										
20 Wed	JZ/RJG/RIG				(US) 10/019,134					
April 2002										
04 Thu	JZ/RJG/RIG				(US) 09/873,827					
24 Wed	JZ/RJG/RIG				(US) 10/056,694					
24 Wed	JZ/RJG/RIG				(US) 10/056,168					
June 2002										
06 Thu	JZ/RJG/RIG				(US) 10/091,819					
07 Fri	JZ/RJG/RIG				(US) 09/731,331					
07 Fri	JZ/RJG/RIG				(US) 09/731,331					
26 Wed	JZ/RJG/RIG				(JS) 09/893,148					
26 Wed	JZ/RJG/RIG				(JS) 10/106,751					
July 2002										
03 Wed	JZ/RJG/RIG				(JS) 10/115,401					
14 Sun	JZ/RJG/RIG				(JS) 60/332,289					
21 Sun	JZ/RJG/RIG				(JS) 60/313,898					

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	EXT
DUE	PARA						EXT	AVAILABLE	
July continued...									
22 Mon	JZ/RJG/RIG				(US) 10/127,736				
29 Mon	JZ/RJG/RIG				(US) 10/197,036				
29 Mon	JZ/RJG/RIG				(US) 10/106,739				
31 Wed	JZ/RJG/RIG				(US) 09/774,942				
August 2002									
07 Wed	JZ/RJG/RIG				(US) N/A				
09 Fri	JZ/RJG/RIG				(US) 10/142,300				
09 Fri	JZ/RJG/RIG				(US) 60/371,561				
14 Wed	JZ/RJG/RIG				(US) 60/332,289				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
22 Thu	JZ/RJG/RIG				(US) 10/153,047				
22 Thu	JZ/RJG/RIG				(US) 10/152,941				
22 Thu	JZ/RJG/RIG				(US) 10/153,037				
22 Thu	JZ/RJG/RIG				(US) 10/154,249				
22 Thu	JZ/RJG/RIG				(US) 10/153,040				
22 Thu	JZ/RJG/RIG				(US) 10/153,007				
22 Thu	JZ/RJG/RIG				(US) 10/153,063				
24 Sat	JZ/RJG/RIG				(US) 09/939,145				
26 Mon	JZ/RJG/RIG				(US) 09/893,148				

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	AVAILABLE
DUE	PARA						EXT	EXT		
September 2002										
06 Fri	JZ/RJG/RIG				(US) 6,451,871					
07 Sat	JZ/RJG/RIG				(US) N/A					
14 Sat	JZ/RJG/RIG				(US) 60/332,289					
16 Mon	JZ/RJG/RIG				(US) 09/811,023					
20 Fri	JZ/RJG/RIG				(US) 10/175,656					
21 Sat	JZ/RJG/RIG				(US) 10/225,062					
October 2002										
04 Fri	JZ/RJG/RIG				(US) 09/939,145					
06 Sun	JZ/RJG/RIG				(US) 60/408,714					
07 Mon	JZ/RJG/RIG				(US) N/A					
08 Tue	JZ/RJG/RIG				(US) 10/091,820					
14 Mon	JZ/RJG/RIG				(US) 60/332,289					
19 Sat	JZ/RJG/RIG				(US) 6,440,411					
23 Wed	JZ/RJG/RIG				(US) 09/586,859					
23 Wed	JZ/RJG/RIG				(US) 09/438,684					
24 Thu	JZ/RJG/RIG				(US) 10/202,758					
31 Thu	JZ/RJG/RIG				(US) N/A					
November 2002										
07 Thu	JZ/RJG/RIG				(US) 60/347,995					
07 Thu	JZ/RJG/RIG				(US) 60/347,995					

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	AVAILABLE
DUE	PARA						EXT	EXT		
November continued...										
07 Thu	JZ/RJG/RIG				(US) 60/347,995					
07 Thu	JZ/RJG/RIG				(US) 60/347,995					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) N/A					
07 Thu	JZ/RJG/RIG				(US) 10/213,972					
07 Thu	JZ/RJG/RIG				(US) N/A					
11 Mon	JZ/RJG/RIG				(US) 10/269,394					
14 Thu	JZ/RJG/RIG				(US) 60/332,289					
14 Thu	JZ/RJG/RIG				(US) 60/332,289					
14 Thu	JZ/RJG/RIG				(US) 60/332,289					
16 Sat	JZ/RJG/RIG				(US) 09/858,394					
21 Thu	JZ/RJG/RIG				(US) 10/225,062					
26 Tue	JZ/RJG/RIG				(US) 10/115,401					
28 Thu	JZ/RJG/RIG				(US) 09/697,859					
29 Fri	JZ/RJG/RIG				(US) 09/710,514					
30 Sat	JZ/RJG/RIG				(US) 09/867,827					

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT.
DUE	PARA						EXT	AVAILABLE
December 2002								
04 Wed	JZ/RJG/RIG				(US) 09/873,827	STATUS CHECK	0	None
05 Thu	JZ/RJG/RIG				(US) 10/153,040			one
06 Fri	JZ/RJG/RIG				(US) 09/586,859			Best Inth
11 Wed	JZ/RJG/RIG				(US) 09/755,357			one
12 Thu	JZ/RJG/RIG				(US) 09/901,886			Inth
12 Thu	JZ/RJG/RIG				(US) 09/879,013			one
13 Fri	JZ/RJG/RIG				(US) 09/766,725			Inth
14 Sat	JZ/RJG/RIG				(US) 60/340,410			one
19 Thu	JZ/RJG/RIG				(US) 09/697,861			one
20 Fri	JZ/RJG/RIG				(US) 10/019,134			one
21 Sat	JZ/RJG/RIG				(US) 09/911,218			nth
24 Tue	JZ/RJG/RIG				(US) 09/873,827			nth
26 Thu	JZ/RJG/RIG				(US) 09/893,148			one
26 Thu	JZ/RJG/RIG				(US) 09/893,148			one
30 Mon	JZ/RIG/RJG				(US) 09/698,528			one

CALL-UP DATES

The following items are due beyond the current print through date of 12/31/2002. A "regular" docket will always print advanced call-ups.

January 2003

01 Wed	JZ/RJG/RIG	(US) 09/731,331	F	nth
03 Fri	JZ/RJG/RIG	(US) 09/558,135	F	th
04 Sat	JZ/RJG/RIG	(US) 09/755,357	F	th
06 Mon	JZ/RJG/RIG	(US) 09/901,886	S	e

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

Best Available Copy

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT		
DUE	PARA						EXT	AVAILABLE			
January continued...											
09 Thu	JZ/RJG/RIG				(US) 10/267,377						
09 Thu	JZ/RJG/RIG				(US) 60/347,116						
09 Thu	JZ/RJG/RIG				(US) 60/347,116						
23 Thu	JZ/RJG/RIG				(US) 09/911,221						
23 Thu	JZ/RJG/RIG				(US) 09/911,330						
23 Thu	JZ/RJG/RIG				(US) 09/911,332						
23 Thu	JZ/RJG/RIG				(US) 09/911,218						
24 Fri	JZ/RJG/RIG				(US) 10/056,694						
24 Fri	JZ/RJG/RIG				(US) 10/056,168						
28 Tue	JZ/RJG/RIG				(US) 09/867,827						
30 Thu	JZ/RJG/RIG				(US) N/A						
February 2003											
14 Fri	JZ/RJG/RIG				(US) 60/356,954						
14 Fri	JZ/RJG/RIG				(US) 60/356,954						
14 Fri	JZ/RJG/RIG				(US) 60/356,954						
14 Fri	JZ/RJG/RIG				(US) 60/356,954						
March 2003											
06 Thu	JZ/RJG/RIG				(US) 10/091,820						
06 Thu	JZ/RJG/RIG				(US) 10/091,819						
13 Thu	JZ/RJG/RIG				(US) 60/364,192						
26 Wed	JZ/RJG/RIG				(US) 10/106,751						

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT		AVAILABLE	

END OF REPORT

TOTAL ITEMS SELECTED =

139

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

A4

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	AVAILABLE
DUE	PARA						EXT	AVAILABLE	
March 2002									
23 Sat	JZ/RJG/RJG				JS) 11/385,418				
23 Sat	JZ/RJG/RJG				JS) N/A				
September 2002									
23 Mon	JZ/RJG/RJG				JS) 11/385,418				
23 Mon	JZ/RJG/RJG				JS) N/A				
October 2002									
24 Thu	JZ/RJG/RJG				JS) 11/443,731				
April 2003									
24 Thu	JZ/RJG/RJG				JS) 11/443,731				
April 2004									
16 Fri	JZ/RJG/RJG				JS) 11/406,108				
August 2004									
20 Fri	JZ/RJG/RJG				JS) N/A				
October 2004									
16 Sat	JZ/RJG/RJG				US) 11/406,108				
January 2005									
10 Mon	JZ/RJG/RJG				US) 10/738,921				
20 Thu	JZ/RJG/RJG				US) 10/969,280				
February 2005									

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>February continued...</i>								
20 Sun	JZ/RJG/RJG			(US)	N/A			
March 2005								
08 Tue	JZ/RJG/RJG			(US)	11/007,442			
10 Thu	JZ/RJG/RJG			(WO)	PCT/US03/1813			
15 Tue	JZ/RJG/RJG			(US)	11/012,658			
April 2005								
05 Tue	JZ/RJG/RJG			(US)	11/029,619			
19 Tue	JZ/RJG/RJG			(US)	10/522,443			
July 2005								
12 Tue	JZ/RJG/RJG			(US)	11/012,658			
12 Tue	JZ/RJG/RJG			(US)	10/980,589			
26 Tue	JZ/RJG/RJG			(US)	10/991,124			
28 Thu	JZ/RJG/JZ			(US)	60/591,704			
28 Thu	JZ/RJG/JZ			(US)	60/591,704			
August 2005								
23 Tue	JZ/RJG/RJG			(US)	10/736,994			
25 Thu	JZ/RJG/RJG			(US)	11/137,195			
25 Thu	JZ/RJG/RJG			(US)	11/137,181			
30 Tue	JZ/RJG/KAB			(US)	11/148,104			
30 Tue	JZ/RJG/KAB			(US)	11/147,594			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
September 2005										
01 Thu	JZ/RJG/KAB				(US) 11/216,366					
14 Wed	JZ/RJG/RJG				(US) 11/076,391					
29 Thu	JZ/RJG/KAB				(US) 11/226,725					
October 2005										
04 Tue	JZ/RJG/KAB				(US) 11/196,908					
13 Thu	JZ/RJG/KAB				(US) 11/243,930					
13 Thu	JZ/RJG/KAB				(US) 60/618,157					
18 Tue	JZ/RJG/RJG				(US) 6,955,832					
21 Fri	JZ/RJG/RJG				(US) 11/110,059					
November 2005										
01 Tue	JZ/RJG/KAB				(US) 11/216,366					
04 Fri	JZ/RJG/KAB				(US) 11/196,908					
05 Sat	JZ/RJG/RJG				(US) 11/243,928					
10 Thu	JZ/RJG/RJG				(WO) PCT/US03/18135					
12 Sat	JZ/RJG/JZ				(US) 11/248,548					
13 Sun	JZ/RJG/KAB				(US) 60/618,157					
22 Tue	JZ/RJG/KAB				(US) 11/284,753					
22 Tue	JZ/RJG/JZ				(US) 11/284,747					
29 Tue	JZ/RJG/KAB				(US) 11/226,725					
30 Wed	JZ/RJG/KAB				(US) 11/216,366					

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
November continued...										
30 Wed	JZ/RJG/KAB				(US) 11/226,604					
December 2005										
06 Tue	JZ/RJG/RJG				(US) 11/137,195					
06 Tue	JZ/RJG/RJG				(US) 11/137,181					
06 Tue	JZ/RJG/RJG				(US) 11/093,819					
09 Fri	JZ/RJG/RJG				(US) 10/864,043					
13 Tue	JZ/RJG/KAB				(US) 11/243,930					
15 Thu	JZ/RJG/RJG				(US) 10/736,994					
17 Sat	JZ/RJG/KAB				(US) 11/305,692					
27 Tue	JZ/RJG/RJG				(US) 11/110,059					
January 2006										
05 Thu	JZ/RJG/RJG				(US) 11/243,928					
10 Tue	JZ/RJG/RJG				(WO) PCT/US03/1813					
22 Sun	JZ/RJG/KAB				(US) 11/284,753					
22 Sun	JZ/RJG/JZ				(US) 11/284,747					
26 Thu	JZ/RJG/RJG				(US) 10/554,652					
28 Sat	JZ/RJG/JZ				(US) 11/248,548					
February 2006										
07 Tue	JZ/RJG/RJG				(US) 6,995,192					
11 Sat	JZ/RJG/RJG				(US) 11/329,697					
17 Fri	JZ/RJG/KAB				(US) 11/305,692					

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT
DUE	PARA						EXT	AVAILABLE	
February continued...									
21 Tue	JZ/RJG/KAB	CI		orporation	(US) 11/284,753				
21 Tue	JZ/RJG/JZ	CI		orporation	(US) 11/284,747				
28 Tue	JZ/RJG/RJG	CI		orporation	(US) 7,004,585				
March 2006									
04 Sat	JZ/RJG/KAB	CI		orporation	(US) 11/365,546				
05 Sun	JZ/RJG/KAB	CI		orporation	(US) 11/148,104				
05 Sun	JZ/RJG/KAB	CI		orporation	(US) 11/147,594				
09 Thu	JZ/RJG/KAB	CI		orporation	(US) 11/365,384				
16 Thu	JZ/RJG/KAB	CI		orporation	(US) 11/305,692				
19 Sun	JZ/RJG/RJG	CI		orporation	(US) 10/470,651				
April 2006									
04 Tue	JZ/RJG/KAB	CI		orporation	(US) 60/658,930				
04 Tue	JZ/RJG/RJG	LP		orporation	(US) 7,022,654				
09 Sun	JZ/RJG/RJG	CI		orporation	(US) 11/243,928				
11 Tue	JZ/RJG/RJG	CI		orporation	(US) 11/329,697				
20 Thu	JZ/RJG/RJG	LP		orporation	(US) 10/969,255				
21 Fri	JZ/RJG/RJG	CI		orporation	(US) 11/385,418				
May 2006									
04 Thu	JZ/RJG/KAB	CL		orporation	(US) 11/365,546				
04 Thu	JZ/RJG/KAB	CL		orporation	(US) 11/415,938				
05 Fri	JZ/RJG/KAB	CL		orporation	(US) 60/677,964				

Page 5

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT
DUE	PARA						EXT	AVAILABLE
May continued...								
09 Tue	JZ/RJG/RJG	C		Corporation	(US) 7,040,756			
09 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/365,384			
16 Tue	JZ/RJG/RJG	C		Corporation	(US) 10/522,443			
16 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/196,908			
16 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/216,366			
18 Thu	JZ/RJG/RJG	C		Corporation	(US) 6,737,661			
18 Thu	JZ/RJG/RJG	C		Corporation	(US) 11/406,108			
22 Mon	JZ/RJG/KAB	C		Corporation	(US) 11/284,753			
22 Mon	JZ/RJG/JZ	C		Corporation	(US) 11/284,747			
30 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/226,725			
June 2006								
01 Thu	JZ/RJG/KAB	C		Corporation	(US) 11/365,384			
13 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/226,604			
13 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/243,930			
17 Sat	JZ/RJG/KAB	C		Corporation	(US) 11/305,692			
21 Wed	JZ/RJG/RJG	C		Corporation	(US) 11/385,418			
30 Fri	JZ/RJG/RJG	C		Corporation	(US) 11/443,731			
30 Fri	JZ/RJG/RJG	C		Corporation	(US) N/A			
July 2006								
04 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/415,938			
14 Fri	JZ/RJG/RJG	C		Corporation	(US) N/A			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT	EXT	AVAILABLE
DUE	PARA						EXT	AVAILABLE	
July continued...									
18 Tue	JZ/RJG/RJG	CL^		poration	(US) 11/406,108				
27 Thu	JZ/RJG/RJG	CL^		poration	(US) 11/093,820				
27 Thu	JZ/RJG/RJG	CL^		poration	(US) 11/412,650				
August 2006									
01 Tue	JZ/RJG/RJG	CL^		poration	(US) 11/329,697				
10 Thu	JZ/RJG/RJG	CL^		poration	(US) N/A				
12 Sat	JZ/RJG/RJG	CL^		poration	(US) 10/797,707				
12 Sat	JZ/RJG/RJG	CL^		poration	(US) N/A				
23 Wed	JZ/RJG/RJG	CL^		poration	(US) 11/065,145				
30 Wed	JZ/RJG/KAB	CL^		poration	(US) 60/636,930				
31 Thu	JZ/RJG/RJG	CL^		poration	(US) 11/443,731				
31 Thu	JZ/RJG/RJG	LPA		poration	(US) 60/712,862				
31 Thu	JZ/RJG/RJG	LPA		poration	(US) 60/712,862				
September 2006									
01 Fri	JZ/RJG/RJG	CL^		poration	(US) 10/476,030				
03 Sun	JZ/RJG/RJG	CL^		poration	(US) 10/287,730				
04 Mon	JZ/RJG/KAB	CL^		poration	(US) 11/365,546				
09 Sat	JZ/RJG/KAB	CL^		poration	(US) 11/365,384				
14 Thu	JZ/RJG/RJG	CL^		poration	(US) N/A				
21 Thu	JZ/RJG/RJG	CL^		poration	(US) 6,793,973				
22 Fri	JZ/RJG/RJG	CL^		poration	(US) 10/676,173				

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT
DUE	PARA						EXT	AVAILABLE	
September continued...									
23 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/088,089				
23 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/416,260				
23 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 60/719,878				
27 Wed	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/654,196				
28 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/007,442				
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/706,208				
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/093,820				
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/093,819				
October 2006									
05 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 6,800,225				
07 Sat	JZ/RJG/KAB	CLV-		CIBA Vision Corporation	(US) 10/654,114				
10 Tue	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) N/A				
12 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) N/A				
14 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/937,140				
26 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 6,808,262				
26 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/554,652				
November 2006									
02 Thu	JZ/RJG/RJG	CLV-		IBA Vision Corporation	(US) 6,811,805				
02 Thu	JZ/RJG/RJG	CLV-		IBA Vision Corporation	(US) 6,811,259				
04 Sat	JZ/RJG/KAB	CLV-		IBA Vision Corporation	(US) 11/415,938				

CALL-UP DATES The following items are due beyond the current print through date of 11/14/2006. A "regular" docket will always print advanced call-ups.

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2 PARA		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
November 2006								
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,206			
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,206			
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,215			
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,215			
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,148			
16 Thu	JZ/RJG/RJG	LP		ation	(US) 60/737,148			
23 Thu	JZ/RJG/RJG	CL		ation	(US) 6,821,108			
23 Thu	JZ/RJG/RJG	CL		ation	(US) 11/416,260			
December 2006								
07 Thu	JZ/RJG/RJG	CL		ation	(US) 6,827,966			
14 Thu	JZ/RJG/RJG	CL		ation	(US) 60/750,195			
14 Thu	JZ/RJG/RJG	CL		ation	(US) 60/750,195			
28 Thu	JZ/RJG/RJG	CL		ation	(US) 6,835,410			
February 2007								
01 Thu	JZ/RJG/RJG	CL		ation	(US) 6,849,210			
END OF REPORT							TOTAL ITEMS SELECTED = 150	



Patent Design General Matters Reports Tools

Save

☐ Critical Dates

Filing	14 Mar 2000	09/525158
--------	-------------	-----------

Publication

Grant

Abandon

Expiration	14 Mar 2020
------------	-------------

Next Annuity

Current Status 14 Mar 2000 Filed

Table 1

☐ Include Annuities and Taxes

A

1

1
















































1


77 Feb. 2000

1

L

1

		Office Action (3 Months)	!!!	12 Jun 2001			26 Jun 2002	
		Response to Office Action (3 Months)	!!!	21 Jul 2001			26 Jun 2002	
		Submission to PTO	Ciba	16 Jul 2000			26 Jun 2002	
		Information disclosure statement	Ciba	14 Jun 2000			26 Jun 2002	
		Response to office action (2 months)	US	10 May 2002			10 May 2002	
		Office action (2 months) Mail Date	Ciba				10 Mar 2002	
		Office action	PATSYS	12 Jun 2001			21 May 2001	
		Filed	09/525158				14 Mar 2000	
		Filing decision					01 Jan 1980	
 Cancel  Save								



Martha-J Martin/CV/Novartis
06/09/2008 12:38 PM

To Jian Zhou/CV/Novartis@PH
cc
bcc
Subject Fw: Question about Patsy Docketing

FYI

Martha J. Martin
CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097
Phone: +1 678-415-3334
Fax: +1 678-415-3068
Email : martha-j.martin@cibavision.com

CIBA VISION

----- Forwarded by Martha-J Martin/CV/Novartis on 06/09/2008 12:38 PM -----

Linda Rothwell/GP/Novartis
06/09/2008 09:30 AM

To Martha-J Martin/CV/Novartis@PH
cc
Subject Re: Question about Patsy Docketing

That is a foreign filing docket date, which was always entered by Basel.

Linda Rothwell
Novartis Pharmaceuticals Corporation
PH, LGL-Patent Data Mgmt
USEH, 104-3J26
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
USA
Phone: +1 862 7787906
Fax: +1 973 7818064
Email : linda.rothwell@novartis.com

 **NOVARTIS**

Martha-J Martin/CV/Novartis



Martha-J Martin/CV/Novartis
06/09/2008 07:51 AM

To Linda Rothwell/GP/Novartis@PH
cc
Subject Question about Patsy Docketing

Jian had a question about what "Reminder Letter" (performed December 15, 2005) indicates for

application number 09/525,158. What was this used for?

Thanks,
Martha

Martha J. Martin
CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097
Phone: +1 678-415-3334
Fax: +1 678-415-3068
Email : martha-j.martin@cibavision.com

CIBA  **VISION™**

C

CASE
DIVISION OF
CONTINUATION IN PART OF
PCT
FILED
SERIAL NO.
FILED

INVENTOR Witt, Thomas, et al

SERIAL NO. 09/525,158 FILED

TITLE Organic Compounds

ASSIGNEE

ASSIGNMENT RECORDED REEL FRAME

09/280,510 filed 3/30/99
60/83,047 filed 3/14/00

OFFICE ACTIONS

AMENDMENTS

3/14/00 - Filed Case

EL282111607US

5/16/00 - Missing Parts
5/16/00 - Missing Receipt

6/7/00 - Response to Miss Pts.

6/21/00 - Filing Receipt

8/30/00 - Filed IDS

3/12/01 - Office Action

4/8/01 - Response to Office ^{Amend A.} Action

6/21/01 - received notice of NON-comp.

Amendment (37 CFR 1.121)

7/3/01 - Responded to Notice of
Non-compliance amendment

4/5/02 - Notice of Abandonment

5/16/02 - Response to Notice of Abandonment

Petition to Withdraw Holding of ABD.

US CB 02 Postcard

09-11-07 - Petition to Revive Application

Abandoned Unintentionally

02-20-08 - Petition Dismissed

ALLOWED FINAL FEE PAID

PATENT NO. DATE

10# 97047

CC/V-30880/4/C6V2112

09/525,158

CONFIDENTIAL

D1



Novartis Corporation
Interoffice Correspondence

Telephone: 770-418-3173
Fax: 770-418-3068

Date: June 7, 1999

To: Mike Dammann Lance Lipscomb
Peter Herbrechtsmeier Scott Meece
Barbara Heyl Paul Nicolson
Stuart Heap Jurgen Vogt
John Lally Greg White

From: Jörg Dietz
Mike Lee

Subject: **Optics Intellectual Property Steering Committee**
Second Quarter Meeting - June 9, 1999
9:00 a.m. - 12:00 noon - JCA - International Video Conference Room

Attached is an outline of the topics for discussion at the June IPSC meeting. The meeting will be held in the International Video Conference Room (JCA-4N) and a Basle location.

Attachments

c: Glen Bradley
Kim Brazzell
Karen Copeland
Mike Glynn
Steve Schuster

CONFIDENTIAL

INTELLECTUAL PROPERTY STEERING COMMITTEE

SCHEDULE FOR MEETING

9:00 a.m. - 12:00p.m.

- I. OPEN ISSUES FROM MARCH MEETING
- II. ALL TRADEMARK ISSUES
- III. LITIGATION & OPPOSITION ISSUES
- IV. MAINTENANCE ISSUES
- V. CURRENT PREPARATION AND PROSECUTION ISSUES
- VI. OPINIONS & ADVICE
- VII. BUSINESS DEVELOPMENT & LICENSING

ATTACHMENTS

Attachment A - Entscheidlisten (Decision List) (sent 5/27/99)
Attachment B - Foreign Filing Country Lists

CONFIDENTIAL

I. ACTION ITEMS FROM DECEMBER 1998 MEETING

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
			M. Lee
			. Meece . Lee Vogt
			. Lee Dietz
			Lee
			Lee Liphardt
			Dietz
			Lee

II. ALL TRADEMARK ISSUES

III. LITIGATION & OPPOSITION ISSUES

A. *OPPOSITION*

Ot

B. PENDING LITIGATION**C. QUESTION OF INFRINGEMENT****IV. MAINTENANCE ISSUES**

A. Entscheidlisten (Decision List) - Sent to attendees.

V. CURRENT PREPARATION / PROSECUTION ISSUES**A. U.S. PREPARATION & PROSECUTION**

1. Preparation Prioritization

2. Recently Filed

a) CL/V-30880/P1/CGV2112 - Hirt, et al, Organic Compounds

3. Recently issued patents, notice of allowance, issue notification:

Issued Patents - U.S.:

Case	Inventor	Title
CL/V-19790	Boneberger, et al	Process and Apparatus for the Manufacture of a Contact Lens (Patent No. 5,894,002 - 4/13/99)

Notice of Allowance:

Case	Inventor	Title
CL/V-20321	Mueller, B.	Crosslinked Polymers Containing Salt Structures (08/875,530)
CL/V-20676	Nicolson, et al	Extended Wear Ophthalmic Lens (09/108,714)

B. NON-U.S. PREPARATION & PROSECUTION

1. Patent Applications filed since last IPSC

a) CL/V-30880/CGV2112 - Priority March 30, 1999 - Dangling Chains (Hirt et al)

CONFIDENTIAL

2. Foreign filings (decisions due)

(P)

ring

3. PCT: Entering of National Phase (decisions due)

a) (

mber

b) (

ity
ision

c) (

ion-
CV/3.

d) C

oulding
was

4. EP Patents Allowed - Decision on National Validation Due

a) C

ction

b) C

c) C

etal (l

d) C

PVA

e) C

f) C

CONFIDENTIAL

5. Patents issued since last IPSC (other than US patents)

This information will be reported at September IPSC.

6. Partial or Worldwide Abandonment (decisions due)

VI. OPINIONS & ADVICE

VII. BUSINESS DEVELOPMENT & LICENSING

VIII. MISCELLANEOUS

- 1999 IPSC Schedule - 9:00 - 12:00 noon (Atlanta time)

September 15, 1999

December 8, 1999

CONFIDENTIAL

M	=	Maintain in all countries.
CV/B	=	Maintain on blocking list.
CV/D	=	Maintain on defensive list.
ABD	=	Abandon case in all countries.
LIC	=	Offer to Optics Licensing and decide on abandonment if no interest at IPSC.
US	=	Maintain in U.S. only.

Basel Case No.	CIBA Vision No.	Last IPSC Decision 6/98	Reason
CL/V 16			
CL/V 16			
CL/V 16			
CL/V 16			
CL/V 16			
CL/V 16			
CL/V 16			
CL/V 17			
CL/V 19			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 17			
CL/V 18			
CL/V 18			
CL/V 19			
CL/V 19			
CL/V 19			
CL/V 19			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 20			
CL/V 21			
CL/V 21			
CL/V 21			
CL/V 21			
CL/V 21			
CL/V 21			

CONFIDENTIAL

Attachment B

Foreign Filing Standard Country Lists CV/1, CV/2, CV/3, CV/4, CV/D and CV/B

[illegible]

CONFIDENTIAL

CV/1	CV/2	CV/3	CV/4	CV/D	CV/B
US: USA *	US	US	US	US	US

* designates: country can be designated in a PCT patent application as of September 1997

CONFIDENTIAL

CONFIDENTIAL

D2

CONFIDENTIAL



Novartis Corporation
Interoffice Correspondence

Telephone: 678-415-3173
Fax: 678-415-3068

Date: December 23, 1999

To: Erich Bauman
Olivia Brown
Mike Dammann*
Lily He
Barbara Heyl*
John Lally (C. Morris*)

Lance Lipscomb*
Scott Meece*
Paul Nicolson*
Tom Paul*
Jürgen Vogt
Steve Wilkin

From: Mike Lee*
Rob Gorman*
Jörg Dietz*

Subject: Optics Intellectual Property Steering Committee
Fourth Quarter Meeting - December 8, 1999
Summary

Attached is a summary of the December 1999 IPSC meeting.

Attachment

c: Glen Bradley
Kim Brazzell
Peter Herbrechtsmeier
Anneliese Hassenbürger*
Stuart Heap
Bernd Liphardt
Robin Terrell

Next Meeting: March 8, 2000

9:00 a.m. - 12:00 noon

International Video
Conference Room - JCA - 4N

*Denotes attendees.

30167 -> CV/B unless P. Herbrechtsmeier address diff B

CONFIDENTIAL

1) NEW ACTION ITEMS

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. Send out email reminder regarding B.I. " " " "			
2.			er
3.			
4.			
5.			ice
6.			
7.			
8.			
9.			
10.			
11.			
If product is still in use.			U. DICK

CONFIDENTIAL

III. LITIGATION / OPPOSITION ISSUES

Case No.	Title	
		on
		on
		filed.

IV. MAINTENANCE ISSUES

V. FOREIGN FILING DECISIONS

Case No.	Project/Product	Filing List	Reasoning
CLV-30880/CGV2112		CV/D	Oxacon / Dangling chains
			Is

VI. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CL			
CL			

VII. EP VALIDATION DECISIONS

Case No.	Project/Product	Validate in EP?	Reasoning
CLV		yes, all countries	on

CONFIDENTIAL

VIII. MAINTENANCE DECISIONS (Entscheidlisten)

[illegible]

NOTE:

2000 IPSC OPTICS

March 8, 2000

June 14, 2000

September 6, 2000

December 6, 2000

9:00 - 12:00 noon

JCA - 4N - International Video Conference Room

D3

Memorandum



Date: April 17, 2001

To: Erich Bauman
Olivia Brown
Barbara Heyl*
Antoinette Lachat
John Lally*
Karen Lindley*

Lance Lipscomb*
Scott Meece*
Paul Nicolson
Tom Paul
Jürgen Vogt*

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Jörg Dietz*
Richard Gearhart*
Rob Gorman*

Subject: Optics Intellectual Property Steering Committee
First Quarter Meeting - March 7, 2001
Summary

Attached is a summary of the March 7, 2001 IPSC meeting.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell

Remaining 2001 IPSC Meetings: June 6;
September 5; December 5

* Denotes attendees.

Memorandum

I. ACTION ITEMS FROM MARCH MEETING

ACTION ITEM	DUE DATE	COMPLETE	RESPONSIBLE PARTY/PARTIES
1. for C			J. Lally
2. to			R. Gearhart
3. Send Lance Lipscomb the specification of CV 150, for review.			R. Gearhart

II. FOREIGN FILING DECISIONS

[illegible]

some from
US

III. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CL/V-30		LNS-10	
CL/V-30	IE 62	LNS-Man + ID	
CL/V-30		LNS-10 + IE	
CL/V-30		LNS-B6	
CL/V-30880		LNS-B6	
CL/V-30		LNS-Manu	
SU/V-31		SUV-14	
SUV-31		SUV-35	
WJ - 76		LNS 10	
WJ - 76			See action item.

Memorandum

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-20		S	
CLV-19		S	
CLV-30		S	

Memorandum

DECISION LIST

VII. MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 3/01	Reason
CLV- 161			
CLV 162			
CLV- 168			
CLV 173			
CLV- 178			
CLV 184			
CLV- 188			
CLV 193			
CLV 194			
CLV- 197			
CLV 197			
CLV- 201			
CLV 202			
CLV 202			
CLV- 202			
CLV 202			
CLV- 202			
CLV 206			
CLV 206			
CLV- 206			
CLV 206			
CLV- 210			
CLV 210			
CLV- 211			
CLV 211			
CLV- 301			
CLV 301			
CLV- 301			
CLV 301			
CLV- 302			
CLV 303			
CLV- 303			
CLV 307			
CLV- 307			
CLV 307			
CLV- 311			
CLV 311			

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 3/01	Reason
CLV- 31			
CLV 31			
CLV- 31			
CLV 31			
CLV- 31			
CLV 31			
CLV- 31			
CLV 31			
LPV- 15		M - All	G
LPV- 16		M - All	C
LPV- 17		M - All	M
LPV- 17		M - CV/B	E
LPV- 17		M - US	
LPV- 17			
LPV- 17		M - US	
LPV- 20		M - All	Added in US.
LPV- 30			
SUV- 19		M - All	Deleted
SUV- 21		M - CV/B	
SUV- 30		M = All	
SUV- 31		M - All	

D4

Memorandum



Date: July 19, 2001

To: Erich Bauman
Barbara Heyl
Antoinette Lachat
John Lally*
Karen Lindley*
Roger Lopez*
Scott Meece
Lance Lipscomb
Tom Paul
Jürgen Vögt*

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Jörg Dietz*
Richard Gearhart*
Rob Gorman*
Jian Zhou*

Subject: Optics Intellectual Property Steering Committee
Second Quarter Meeting - June 6, 2001
Summary

Attached is a summary of the June 6, 2001 IPSC meeting.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell

Remaining 2001 IPSC Meetings:
September 5; December 5

* Denotes attendees.

Memorandum

I. ACTION ITEMS FROM JUNE MEETING

ACTION ITEM	DUE DATE	COMPLETE	RESPONSIBLE PARTY/PARTIES
1. J. b;			Gearhart Dietz
2. de			P. Nicolson
3.			J. Dietz
4.			J. Dietz
5.			R. Gearhart
6.			R. Gearhart
7. 1			R. Gearhart
8.			R. Gearhart
9.			J. Dietz
1. E			P. Nicolson
			R. Gearhart
			R. Gearhart
			R. Gearhart/J. Dietz
			R. Gearhart/J. Dietz
			R. Gorman

II. FOREIGN FILING DECISIONS

Case No.	Project/Product	Filing List	Reasoning
CL/V-31		LNS B6	See action item.
CL/V-31		LCP14	See action item.
LP/V-31		LCP 36	
LP/V-31		LCP14	See action item.
CL/V-31		CLR 11	See action item.
CL/V-31		LNS 10	
CL/V-31		LNS Manu	

Memorandum

LP/V-31		LCP 36	
---------	--	--------	--

III. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-317 WE		CLR 18	See action item.
SU/V-30	Artificial Cornea	SUR B6	See action item.
CLV-310 VE		LNS Manu	
CLV-310		LNS B6	
CLV-310		LNS 10	
CLV-310		LNS B6	

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-300		LNS23+IE	See action item.
CLV-19		LNS B6	
CLV-21		LNS 10	
CLV-20		LNS B6	

DECISION LIST

VII. MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CLV- 16		M - LNS B6	
CLV 16		M - LNS B6	
CLV- 16	CGV	M - LNS B6	
CLV 16	CGV	ABD or LNSB6	See action item.
CLV- 17	CGV	M - LNS B6	See action item.
CLV 17	CGV	ABD	
CLV- 17	CGV	ABD	
CLV 17	CGV	R - LNS B6	See action item.
CLV 17	CGV	M-LNSB6	
CLV- 17	CGV	M-US	
CLV 17	CVE	M - LNS B6	
CLV- 17	CVE	M - LNS B6	See action item.
CLV 17	CVE	M - LNS Manu	
CLV 18	CVE	M - US	
CLV- 18	CVE	M - LNS B6 + NL	

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CLV 18	CGV 1503	M - ALL	
CLV- 19	CVE 80	ABD	See action item.
CLV 19	CGV 1000	M - LNS B6	
CLV 19		M - LNS B6	
CLV- 19	CVE 40	M - ALL	
CLV 20	CVE 52	M - ALL	
CLV- 20		M - LNS B6	Backup for DAILIES.
CLV 20		M - LNS B6	
CLV- 20		M - ALL	
CLV 20		M - ALL	
CLV- 20		M - ALL	
CLV 20		M-ALL	
CLV- 20	CGV 1007	M - ALL	
CLV 21	CVE 50	R - LNS 23 + IE	
CLV- 21	CVE 50	M - LNS Manu	
CLV 21		M - CV/D	
CLV- 21		M - LNS B6	
CLV 21	CGV 1000	M - ALL	
CLV- 30	CGV 1000	R - LNS 23	
CLV 30		M	
CLV- 30	CVE 50	M - EP/US	
CLV 30			Will discuss at next IPSC meeting.
CLV- 30		M - ALL	
CLV 30880	CGV 2002		Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV 31			Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV- 31			Discuss at June 2002 meeting.
CLV- 31	WEJ 0400		Discuss at June 2002 meeting.
CLV- 31	WEJ 7500		Discuss at June 2002 meeting.
CLV 31	WEJ 0200		Discuss at June 2002 meeting.
CLV- 31	WEJ 1100		Discuss at June 2002 meeting.
CLV 31	WEJ 1000		Discuss at June 2002 meeting.
CLV- 31	WEJ 1000		Discuss at June 2002 meeting.
CLV- 31	WEJ 1500		Discuss at June 2002 meeting.
CLV- 31	WEJ 1550		Discuss at June 2002 meeting.
CLV- 31	WEJ 1000		Discuss at June 2002 meeting.
CLV- 31	WEJ 0400		Discuss at June 2002 meeting.
CLV- 31	WEJ 0400		Discuss at June 2002 meeting.
CLV- 31	WEJ 0400		Discuss at June 2002 meeting.
CLV- 31	WEJ 0400		Discuss at June 2002 meeting.

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
CLV- 34			Discuss at June 2002 meeting.
LPV- 19	CVE	M- ALL	
LPV- 19	CGV	M- LCPB6	
LPV- 19	CGV	M - ALL	
LPV- 20	CGV	M - US	
LPV- 20			Discuss at June 2002 meeting.
SUV- 20			Discuss at June 2002 meeting.
SUV- 20	MEC 4	M - ALL	
SUV- 20			Discuss at June 2002 meeting.
SUV- 20			Discuss at June 2002 meeting.
SUV- 20		R - SUR 14	See action item.
SUV- 20			Discuss at June 2002 meeting.
SUV- 20			Discuss at June 2002 meeting.

Memorandum

**Foreign Filing Standard Country Lists for the LCP BUSINESS
(And PROPOSED list for the SURGICAL BUSINESS,**

LCP und SUR Lists: Countries	LCP: B(6)	LCP: 14	LCP: 36		SUR B(6)	SUR 14	SUR 36
US: United States *	yes	yes	yes		yes	yes	yes
Europe:							

* designates: country can be designated in a PCT patent application as of March 2001

3/14/01

Memorandum

Foreign Filing Standard Country Lists for the LENS BUSINESS

(The WJ lists are PROPOSED only presently; "WJ" means in particular: for tinted lenses)

[illegible]

* designates: country can be designated in a PCT patent application as of March 2001

06/01/01

D5

CONFIDENTIAL



A Novartis Company

Date: September 19, 2001

To: Erich Bauman* Lance Lipscomb
Roger Lopez* Scott Meece*
Barbara Heyl Paul Nicolson
Antoinette Lachat* Tom Paul*
John Lally Jürgen Vogt*
Karen Lindley Jörg Dietz

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Richard Gearhart
Rob Gorman
Jian Zhou

Subject: Optics Intellectual Property Steering Committee Minutes
Third Quarter Meeting – September 5, 2001
9:00 a.m. - 12:00 noon - JCA - International Video Conference Room

Summary

Attached is an outline of the topics discussed at the September 5th IPSC meeting. Please review decisions and note new action items required prior to the next IPSC meeting to be held on December 5th. The meeting will be held in the International Video Conference Room (JCA-4N) and a Basle location.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell
Roland Carlen

Members Absent*

CONFIDENTIAL

INTELLECTUAL PROPERTY STEERING COMMITTEE

SCHEDULE FOR MEETING

9:00 a.m. - 12:00p.m.

- I. OPEN ISSUES FROM JUNE MEETING
- II. ALL TRADEMARK ISSUES
- III. MAINTENANCE ISSUES
- IV. CURRENT PREPARATION AND PROSECUTION ISSUES
- V. LITIGATION & OPPOSITION ISSUES
- VI. OPINIONS & ADVICE
- VII. BUSINESS DEVELOPMENT & LICENSING

ATTACHMENTS

Attachment A - Entscheidlisten (Decision List) (has been sent under separate cover)

Memorandum

I. NEW ACTION ITEMS FROM SEPTEMBER 2001 MEETING MINUTES

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. a) by b) Lip			
2. F			
3.			
4.			
5. (
6. I			
7. (
8.			
9. (
10.			
11.			
12.			
13.			
14.			
15.			
16.			
17S			I. Paul

Memorandum

II. ACTION ITEMS COMPLETED FROM SEPTEMBER 2001 MEETING MINUTES

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. CL/V-30880 - PCT Candidate.		Completed	R. Gearhart
2.			
3.			
4.			
5.			
6. CL/V-30880 - PCT Candidate.		Completed	R. Gearhart
7. CL/V-30880 - PCT Candidate.		Completed	R. Gearhart
8. CL/V-30880 - PCT Candidate.		Completed	J. Dietz
9.			P. Nicolson
10.			R. Gearhart
11.			R. Gearhart
12.			R. Gearhart/J. Dietz
13. CL/V-30880 - PCT Candidate.		LNSB6 (+ Indonesia)	R. Gearhart/J. Dietz
14.			R. Gorman

Memorandum

III. ALL TRADEMARK ISSUES (No Update Provided)

IV. MAINTENANCE ISSUES

- A. Entscheidlisten (Decision List) – Was sent previously.
- B. WJ supplemental US list

V. CURRENT PREPARATION / PROSECUTION ISSUES

A. *U.S. PREPARATION & PROSECUTION*

1. Preparation Prioritization PRC Update - RIG
2. Recently Filed: Information Only (See **Section I** Filing Status Report).
3. Recently issued patents: Information Only

Patent No.	Date	Case	Inventor	Title
6,271, 233 B1	August 7, 2001	OP/V-30610/A/CGV 2024	Brazzell et al.	Method for Treating Ocular Neovascular Diseases
6, 271, 332 B1	August 7, 2001	CL/V-20677A/PCT	Lohmann et al.	Polyurethanes Made from olxysiloxane/Polyol Macromers
6, 265, 509 B1	July 24, 2001	CL/V-20319/A/PCT /DIV	Muller Beat	Crosslinked Polymers
6, 259, 518 B1	July 10, 2001	CL/V-30611A/CGV 2027	Russell et al.	Wetcell Device For Inspection
6,255, 360 B1	July 3, 2001	SU/V-30898A/CVA	Domschke et al.	Process for the Manufacture of Moldings
6,221, 303 B1	April 24, 2001	CL/V-21235/A/PCT	Steinmann	Ophthalmic Mouldings
6, 225, 367 B1	May 1, 2001	SU/V-30635A/ERT 15	Chaouk et al.	Polymers

Memorandum

B. NON-U.S. PREPARATION & PROSECUTION

1.

2.

d

1

Memorandum

i)

rising
tion

j)

k)

ontact

l)

n for

3. PCT: Entering of National Phase (Decision due):

a)

v.
follow

b)

xygen
:

4. EP Patents Allowed - Decision on National Validation Due

a)

b)

5. Partial or Worldwide abandonment (decisions due): None

VII. LITIGATION & OPPOSITION ISSUES

A. OPPOSITION

1)

proceedings before the EPO in September.

B. PENDING LITIGATION

Memorandum

1. CIBA Vision as a party

- a)

- b)

C. QUESTION OF INFRINGEMENT

VIII. OPINIONS & ADVICE

IX. BUSINESS DEVELOPMENT & LICENSING

XI. MISCELLANEOUS

Remaining 2001 IPSC Meeting December 5, 2001

Memorandum

DECISION LIST SEPTEMBER 5th Meeting

Attachment: MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			tz
CL/V			tz
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V			
CL/V-			
CL/V			
CL/V-			
CL/V			
CL/V-			

Memorandum

Base Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 2			
SU/V 2			

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
SU/V			
SU/V			
SU/V-			
SU/V			
SU/V-			
SU/V			
			Due date October . .

Memorandum

Foreign Filing Standard Country Lists for the LCP BUSINESS

[illegible]

* designates: country can be designated in a PCT patent application as of March 2001

3/14/01

Memorandum

Foreign Filing Standard Country Lists for the LENS BUSINESS

LNS Lists: Countries		LNS: B(6)			R		
US: United States *	yes	yes	yes	yes	yes	yes	yes

* designates: country can be designated in a PCT patent application as of March 2001

06/01/01

D6

Memorandum

Minutes

Confidential



Date: July 5, 2002

To: Rafael Andino
Sheila Bodmer
Scott Hampton
Barbara Heyl*
John Lally*
Karen Lindley*
Lance Lipscomb*
Roger Lopez
Scott Meece
Michael Quinn*
Jürgen Vogt*
Daniel White

From:

Jörg Dietz*
Richard Gearhart
Rob Gorman*
Bernd Liphardt*
Robert Mueller*
Jian Zhou*

Subject:

CIBA Vision Intellectual Property Steering Committee Second Quarter Meeting – June 5, 2002 Summary

Attached is a summary of the June 5, 2002 IPSC meeting. Further meeting dates for 2002 are:

September 4, 2002
December 4, 2002

Attachments

(SEC members will obtain a summarized version)

* Denotes attendees.

→ Glen Bradley
Tim Barabe
Ivan Seragie
Robin Terrell
Roland Carlen
Lens Business
Suppy Boss
Lens Care Boss
Wahlberg v. Stenhat Keep?

Memorandum

Minutes

Confidential

I. ACTION ITEMS FROM JUNE MEETING

[illegible]

Memorandum

Minutes

Confidential

II. FOREIGN FILING DECISIONS

Case No.	Project	Filing List	Reasoning
1			
2			
3			
4			
5			
6			
7			
8			
9			

III. PCT NATIONAL PHASE ENTRY DECISIONS

1			
2			
3			
4			
5			

AU

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
-	-	-	

Memorandum

Minutes

Confidential

V. PARTIAL OR WORLDWIDE ABANDONMENT

✓ 5.1. SU/V-
Decisi

Steele et al.)

Bloch, CSIRO

Au

VI. MAINTENANCE DECISIONS (Entscheidlisten)

Case No.	IPSC Decision 03/2002	Reason
CL/V-30880/CGV 2112	M - LNS B6	

Memorandum

Minutes

Confidential

[illegible]

Memorandum

Minutes

Confidential

Foreign Filing Standard Country Lists for *

a

‘S

[illegible]

* designates: country can be designated in a PCT patent application as of January 2002

Memorandum

Minutes

Confidential

Foreign Filing Standard Country Lists for the LENS BUSINESS

(The CLR lists are applicable in particular for COLOURED lens cases)

LNS Lists: Countries		LNS: B6					
US: United States *	yes	yes	yes	yes	yes	yes	yes

* Designated country can be designated in a PCT patent application as of January 2002

07

Memorandum

Minutes



Date: **June 30, 2003**

To: Rafael Andino*
Sheila Bodmer
Barbara Heyl*
John Lally
Karen Lindley*
Lance Lipscomb*
Roger Lopez

Scott Meece
Tom Paul
Michael Quinn*
Ming Tai
Jürgen Vogt*
Daniel White
Mary Leheny

From: Richard Ross*
Laura Fe*
Richard Gearhart*

Rob Gorman*
Bernd Liphardt
Robert Mueller*
Jian Zhou*

Subject: **CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 4, 2003**

Summary

Attached is a summary of the June 4, 2003 IPSC meeting.
Quarterly meeting dates for 2003 are:

September 3, 2003
December 3, 2003

Attachments

* Denotes attendees.

Memorandum

Minutes

I. ACTION ITEMS FROM JUNE MEETING

[illegible]

Memorandum

Minutes

MEMORANDUM FOR THE RECORD SUBJECT: Meeting with D. H. Moore			

+

Memorandum

Minutes

II. FOREIGN FILING DECISIONS

[illegible]

Enfold?

Memorandum

Minutes

III. PCT NATIONAL PHASE ENTRY DECISIONS

No.	Case	Key Term	Entry Decision
3.1			✓
3.2			CRCECT BIOCUR
3.3			Biocure ✓
3.4			CRCECT (2)
3.5			✓

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision
1.		Biocure
2		CRCECT / Bio
3		CRCECT / Bio
4		DT AB
5		DT AB ✓
6		

V. Partial or Worldwide abandonment (decisions due):

Memorandum

Minutes

VI. MAINTENANCE DECISIONS (Entscheidlisten)

Case No.	IPSC Decision 06/2003	Reason
CLV-30880/CGV 2112	M - LNS B6	

Teilweise
an CIBASC überwacht

☒ ✓
☒ ✓
☒ ✓
☒ ✓
☒ ✓
in
☒ ✓

DHGRID

DTABR.A

Bio
DTMBE :A
DTMBE :A

} Bio

~~✓~~ ?
Bio

✓
✓
Bio
Bio

✓
Bio
✓
Bio
Biosure
Bio
Bio
✓

tot ✓

Memorandum

Minutes

[illegible]

Memorandum

Minutes

Foreign Filing Standard Country Lists

t.

[illegible]

* designates: country can be designated in a PCT patent application as of August 2002

Memorandum

Minutes

Foreign Filing Standard Country Lists for the LENS BUSINESS

(The CLR lists are applicable in particular for COLOURED lens cases)

[illegible]

* designates: country can be designated in a PCT patent application as of August 2002

18

Memorandum

Minutes



Date: June 21, 2004

To: Rafael Andino*
Frans Mahieu
John McNally
Kristina Meier*
Karen Lindley*
Greg White*

Lance Lipscomb*
Michael Quinn
John Lally*
Jürgen Vogt*
Peter Hagmann
MK Raheja

From: Rob Gorman*
Jian Zhou*
Karen Borrelli*

Bernd Liphardt
Robert Karl Mueller*
Laura Fe

Jennifer China*
Jocelyne Straumann* (Minutes)

Subject: CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 2, 2004

Summary

Attached is a summary of the June 2, 2004 IPSC meeting.
Quarterly meeting dates for 2004 are:

September 1st, 2004
December 1st, 2004

Attachments

* Denotes attendees

Memorandum

Minutes

I. Trademarks Update – Kristina Meier

II. March 2004 IPSC ACTION ITEMS DISCUSSED

ACTION ITEM	RESULT
-------------	--------

March 2004 IPSC Meeting: Maintenance decisions on LP/V-Cases (By Karen Lindley, June 4, 2004)

Case	Present Level of maintenance	Decision	Remarks
1			
1			
1			

Memorandum

Minutes

III. Open Issues from JUNE 2004 Meeting

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES

Memorandum

Minutes

1 6 1 7	Mueller
Can be	lli
8. CL/V-30880/CGV 2112, examine against	Rob Gorman, & Jian Zhou
1 A 1 1 co 1 3 1 w 1 A	ew Mueller

IV. FOREIGN FILING DECISIONS

Case	Key Term	Filing List

Case	Key Term	Entry Decision
	Synonym	

Case	Key Term	Entry Decision
CLV 30784/CGV 2000	Alternative Oxadon synthesis	Action Item 5
CLV-30880/CGV 2112	Amphiphilic block copolymers comprising dangling chains	LNS B6 (FR, DE, GB, IT)

CLV-317
Decision : ABD

Case No.	IPSC Decision 06/2004	Reason
CLV-30880/CGV 2112	M – LNS B6	Action Item 8 (Jian Zhou)

D9

Memorandum

Minutes



Date : September 15, 2004

To: Rafael Andino*
Walter Bassett*
John McNally
Kristina Meier
Karen Lindley
Greg White
Michael Quinn*

Lance Lipscomb*
Frans Mahieu
John Lally*
Jürgen Vogt*
Peter Hagmann
MK Raheja*

Ramis Bushay

From: Rob Gorman*
Jian Zhou*
Karen Borrelli*

Bernd Liphardt
Robert Mueller*
Laura Fe*

Sara Carter*
Jennifer China
Jocelyne Straumann* (Minutes)

Subject : CIBA Vision Intellectual Property Steering Committee
Third Quarter Meeting – September 1, 2004

Summary

Attached is a summary of the September 1, 2004 IPSC meeting.
Next meeting date is :

December 1, 2004

Attachments.

* Denotes attendees

Memorandum

Minutes

I. Trademarks

II. June 2004 IPSC ACTION ITEMS DISCUSSED

ACTION ITEM	RESULT
8. CL/V-30880/CGV 2112, examine against :	

Memorandum

Minutes

III. Open issues from September 2004 Meeting

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES
		an
		a
		el
		8
		7
		1
		1
		ig
4. CL/V-30880/CGV 2112, examine against . Don't think it is relevant.		Rob Gorman, & Jian Zhou

Memorandum

Minutes

Negative, according to case		

IV. Litigation Issues

Updates on litigation / opposition as appropriate

V. Maintenance issues

VI. Foreign Filings Decisions

[illegible]

VII. PCT: Entering of national Phase (decisions due):

Case	Key Term	Entry Decision
		lanu

Memorandum

Minutes

VII. EP Patents allowed (decisions due):

[illegible]

VII. Partial or Worldwide abandonment (decisions due) :


- a. SU/V-317, Multifocal IOL, (worldwide abandonment tentatively decided) **Decision : Abd.**
- b. Diagnostic Lens Portfolio, 19 patent families

List of Diagnostic Patent Applications (August 2004)

[illegible]

Memorandum

Minutes



VIII. MAINTENANCE DECISIONS (Entscheidlisten)

[illegible]

Memorandum

Minutes

[illegible]

Memorandum

Minutes

Case No.	IPSC Decision 09/2004	Reason
C		
C		
C		
C		
C		Action Item 11
C		
S		
S		
S		
S		

Memorandum

Minutes

Foreign Filing Standard Country Lists for the LCP BUSINESS (as of June 10, 2004)

LCP Lists: Countries	CV-B6	CV-7		
US: United States *	yes	yes	yes	yes
Europe:				

[illegible]

* designates: country can be designated in a PCT patent application as of August 2004

Memorandum

Minutes

Foreign Filing Standard Country Lists for the LENS BUSINESS (as of June 10, 2004)
(The CLR lists are applicable in particular for COLOURED lens cases)

[illegible]

*designates: country can be designated in a PCT patent application as of August 2004

D/0

Memorandum

Minutes



Date : December 16, 2004

To: Rafael Andino* Lance Lipscomb*
Walt Bassett Frans Mahieu
John McNally* John Lally*
Kristina Meier Jürgen Vogt*
Karen Lindley* Remis Bistras*
Angelika Domschke* Peter Hagmann
MK Raheja*
Michael Quinn* Curt McKenney*

From: Rob Gorman* Bernd Liphardt*
Jian Zhou* Robert Karl Mueller*
Karen Borrelli* Laura Fe*

Sara Carter*
Jennifer China
Jocelyne Straumann* (Minutes)

Subject : CIBA Vision Intellectual Property Steering Committee
Fourth Quarter Meeting – ~~September 1st~~, 2004

December

Summary

Attached is a summary of the December 1, 2004 IPSC meeting.

Quarterly meeting dates for 2005:

March 2nd, 2005
June 1st, 2005
August 31st, 2005
November 30th, 2005

Attachments

* Denotes attendees

Memorandum

Minutes

I. Trademarks

II. September 2004 IPSC action items discussed

ACTION ITEM	RESULT
4. CL/V-30880/CGV 2112, examine against [REDACTED]. Don't think it is relevant.	Done

Memorandum

Minutes

III. Open issues from December 2004 Meeting

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES

IV. Patent Policy

The revised CIBA Vision Patent Policy was discussed and approved

V. Foreign Filing Decisions

Case	Key Term	Filing List

Memorandum

Minutes

Case	Key Term	Filing List
		R

VI. PCT: Entering of National Phase (decisions due):

[illegible]

Memorandum

Minutes

VII. EP Patents allowed (decisions due)

Case	Key Term	Entry Decision

VIII. Further handling of DiLens Patent Applications (Proposal P. Herbrechtsmeier)

A. Licensing out candidates – Maintain until July 2005

Internal Case CL/V	Priority Date	Title/Subject Matter	Status
315			Pending in more than 30 worldwide the US (US-P
319			, EP, JP WO 02/087 429
326			T Phase: Mar 2005
326			T, National Phase:
327			T, National Phase:
328			T, National Phase Jun
328			T, National Phase Jul
328			T, Phase: Aug 2005
328			T, Phase: Aug 2005
329C			T, National Phase:
		Birth control method	

Memorandum

Minutes

Internal Case CL/V	Priority Date	Title/Subject Matter	Status
329			Pending DCT National Phase:
33			ational Phase:
33			Jan 2006
33			Feb 2006
33			Feb 2005
33			May 2005
33			June 2005
		from blood and from ocular fluid	

B. Patent families of minor interest – candidates for abandonment

319	
320	
3289	5
	15
33	
	16

C. Patent families co-owned with Ehrfeld – offer to Ehrfeld/Bayer

328	Pending DCT
328	

Memorandum

Minutes

33	05
33	15

Decision on the further handling of the DiLens Patent Portfolio:

- Include group B patents into the licensing out candidates – maintain group A and group B patents until end of July 2005
- It was approved to offer group C patents to Ehrfeld/BAYER

IX. Maintenance Decisions (Entscheidlisten)

Case No.		IPSC Decision 4/2004	Reason
CLV-171	9	M – JP only	Subject to Gilead-Epoen agreement
CLV-182	17	M – (CV-B6)	
CLV-195		M – (CV-B6, + AU, CA)	
CLV-196		R – (CV 7) - CA	
CLV-197		M – (15 countries)	
CLV-198		M – All (37 countries)	
CLV-199	13	M – (LNS Manu)	
CLV-200		M – All (21 countries)	
CLV-201	19	M – all (= (CV-7) + IE + ES	
CLV-202		M – (CV-B6)	
CLV-203		M – (CV-B6)	
CLV-204	374	M – (CV-B6, + IE)	
CLV-205	1	R – (CV-B6)	
CLV-206	953	M – (CV-B6, + IE)	
CLV-207	957	M – (CV-B6, + IE)	
CLV-208		M – (CV-B6)	
CLV-209	10	M – (CV B6)	
CLV-210	2027	M – (CV-B6)	
CLV-211	2039	M – (LNS Manu)	
CLV-212	2040	M – (LNS Manu)	Subject to Gilead-Epoen agreement
CLV-213	31	M – (LNS Manu)	
CLV-214		M – (CV-B6)	
CLV-215		M – US only	
CLV-216		M – (CV-B6)	Subject to Gilead-Epoen agreement
CLV-217		R – (CV-7)	
CLV-218		M – (CV-B6)	

Memorandum

Minutes

CLV-	R - (CV-7)	
CLV-	M - (CV-7)	
CLV-	M - (CV-7)	
CLV-	M - (CV-B6)	
CLV-	M - (CV-7)	
CLV-	M - (CV-7)	
CLV-	M - (CV-7)	
CLV-	M - (CV-7)	
CLV-	M - (CV-B6)	
CLV-	M - (CV-7)	
CLV-	R - (CV-B6)	
CLV-317	ABD	
CLV-21	M - all	Action Item
CLV-	M - ALL (= (CV-7) + AU - IT - USA	Action Item
CLV-	Reduce lens design to (CV-7) Keep process everywhere	
CLV	M - all (= AR, EP, JP, SG, US)	
LPV	M - All (17 countries)	
LPV	M - (LCP-B6)	
LPV	M - (LCP-B6)	
LPV	M - (LCP-B6)	
LPV	M - (CV 7) + TW	
LPV	M - (LCP 36)	
LPV	M - (CV-7) + TW	
LPV	M - LCP B6	
SUV	M - SUR 14	Action Item

Memorandum

Minutes

ANNEX 1 - CV Foreign Filing Standard Country Lists

[illegible]

*designates: country can be designated in a PCT patent application as of October 2004

D11

Confidential
Memorandum Minutes May 26, 2005



Date: June 15, 2005

Subject: CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – May 26th, 2005

Distribution

Andino Rafael*	Meier Kristina
Basset Walt	Minno George
Bistras Remis*	Mueller Robert Karl*
Borrelli Karen*	Lally John*
Carter Sara	Lindley Karen*
China Jennifer	Liphardt Bernd
Domschke Angelika*	Lipscomb Lance
Fe Laura*	Raheja MK*
Gorman Rob*	Quinn Michael
Hagmann Peter	Vogt Juergen
Mahieu Frans	Ujak Vanessa (Minutes)*
McKenney Curt*	Jian Zhou*

Legend

- | | |
|---|--------|
| I. Open Issues from March 2005 Meeting | p.2 |
| II. New Action Items | p.2 |
| III. Foreign Filing Decisions | p.2, 3 |
| IV. PCT: Entering of National Phase | p.3 |
| V. EP Patents allowed (decisions due) | p.3 |
| VI. Further handling of DiLens Patent Applications
(Proposal P. Herbrechtsmeier) | p.4, 5 |
| VII. Maintenance Decisions | p.6, 8 |
| Annex 1 – CV Foreign Filing Standard Country Lists | p.8 |

Summary

Attached is a summary of the May 26, 2005 IPSC meeting.

Remaining quarterly meeting dates for 2005:

August 31, 2005

November 30, 2005

* Denotes attendees

Confidential
Memorandum Minutes May 26, 2005

I. Open Issues from March 2005 Meeting

Action Items	Responsible	Result
--------------	-------------	--------

II. New Action Items

Action Items	Due Date	Responsible Party/Parties
--------------	----------	---------------------------

III. Foreign Filing Decisions

Case	Key Term	Filing List
CLV-1000000000	the use of marketing customized colored silicon contact	IN NC 22 + MV + IN
CLV-		
CLV-		
CLV-		
CLV-		
CLV-		
CLV-		
CLV-1000000000	the use of marketing customized colored silicon contact	

Confidential
Memorandum Minutes May 26, 2005

Case	Key Term	Filing List
CLV-3		CLV-7
CLV-3		
CLV-3		
CLV-3		
CLV-3		
CLV-3	Contact lens design for large amplitude translation	CLV-7

IV. PCT: Entering of National Phase:

Case	Key Term	Entry Decision
CLV		
CLV		
CLV		
CLV		
CLV		
CLV	et al.)	

V. EP Patents allowed

Case	Key Term	Entry Decision
CLV-312		B, IT)
CLV-313		ES +
		B, IE, IT
LPV-320		
CLV-321		B, IT)
	et al.)	IE

Confidential
Memorandum Minutes May 26, 2005

VI. Further Handling of DiLens Patent Applications (Proposal P. Herbrechtsmeier)
6.1. Group A: Licensing out candidates – Maintain until July 2005

Internal Case CLV	Priority Date	Title/Subject Matter	Status
31552/TEX			to CV-7 nts to Dr. 0 -P
326			SA
327			ISA
328			005
328			0 2005
329			06 National
329			07 National
332			84
333			2006 37
336			2006 e 2006
338		measurement of blood sugar levels from blood in mouth ocular fluid	PCT Filing: June 2005

Confidential
Memorandum Minutes May 26, 2005

6.2 Group B. Patent families of minor interest – candidates for abandonment (Maintain until July 2005)

Internal Case CL/V	Priority Date	Title/Subject Matter	Status
319			
326			
328			
33			

Confidential
Memorandum Minutes May 26, 2005

VII. Maintenance Decisions (Entscheidlisten)

Case No.	Decision	Reason, Action Item
LPV-	M – (CV-7) – CA	
LPV-	M – (CV-7) + AU + TW	
LPV-	M – (CV-7) – CA	
LPV-	M – LCP 36	
CLV-	M – (CV-7) – CA - US	
CLV-	M – (CV-7) – CA - US	
CLV-	M – US only (tentative decision)	Action item
CLV	M – (CV-7) – CA	
CLV	M – (FR, DE, GB, IT)	
CLV	M – (CV Manu) + JP – ID – SG - MY	
CLV	M – (CV-7) – CA	
CLV	M – (CV-7)	
CLV-190	M – US only	
CLV-194	M – (CV-7) – CA	
CLV-197	ABD	
CLV-197	ABD	
CLV-198	ABD	
CLV-198	M – (CV Manu) + JP – ID – SG - MY	
CLV-203	M – (DE, US)	
CLV-203	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – US	
CL	M – US	
CL	M – DE	
CL	M – (CV-7) – CA	
CL	M – (CV-7) – CA	
CL	M – (CV Manu) + JP – ID – SG - MY	
CL	M – (CV-7) + NO + ES + SE	
CL	M – (CV-7) – CA	
CL	M – (CV Manu) + JP – ID – SG - MY	
CL	M – (CV Manu) – ID – SG - MY	
CL	M – (CV Manu) + JP – ID – SG - MY	
CLV-30880/CGV 2112	M – (CV-7) – CA	
CLV-3	M – (CV Manu) + JP – ID – SG - MY	
CLV-3	R – (CV-7)	
CLV-	M – (CV Manu) + JP – ID – SG - MY	ABD AR + TW (IPSC June 2003)
CLV-	M – (CV-7) – CA	

Confidential
Memorandum Minutes May 26, 2005

Case No.	Decision	Reason, Action Item
CLV-313	M - (CV Manu) + JP - ID - SG - MY	
CLV-313	M - (CV-7) + NO + ES + SE	
CLV-316	M - (CV-7) + NO + ES + SE	
CLV-317	M - (GB, JP, MX, US)	
CLV-317	M - All	
CLV-317	M - (CV-7) - CA	
CLV-317	M - All	
CLV-317	M - (DE + US)	IPSC June 2003: R - (DE + US)
CLV-317	M - (CV-7) - CA	
CLV-317	M - (CV-7)	
CLV-317	ABD (tentative decision)	Action Item
CLV-317	ABD (tentative decision)	Action item
CLV-317	M - (DE + US)	
CLV-317	M - US	
CLV-317	M - US	
CLV-317	M - US	
CLV-317	M - US	
CLV-317	M - (CV-7) - CA	
CLV-317	M - (CV-7) - CA	
CLV-317	M - LNS 23	
CLV-317	M - (CV Manu) + JP - ID - SG - MY	
CLV-317	M - (CV Manu) + JP - ID - SG - MY	
CLV-317	M - (CV-7) + NO + ES + SE	
CLV-317	M - (CV-7)	
CLV-318	M - (CV Manu) + JP - ID - SG - MY	
CLV-322	M - (AR, EP, US, TW)	
CLV-322	M - (CV-7)	
CLV-322	M - (CV-7)	
CLV-323	M - (CV Manu) + JP - ID - SG - MY	
CLV-324	M - (CV Manu) + JP + SG - ID - SG - MY	
CV/V-326	M - (CV-7)	


Confidential
Memorandum Minutes May 26, 2005

ANNEX 1 - CIBA Vision Foreign Filing Standard Country Lists

Country:	LNS List:	CV-Manu	CV-7	LNS-23	LCP-36
US: United States*		yes	yes	yes	yes

designates: country can be designated in a PCT patent application as of April 2005

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential



Date : June 23, 2006

Subject : CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 2nd, 2006

Distribution

Bassett Walt*
Bielefeldt Florian*
Bistras Remis*
Borrelli Karen*
Carter Sara*
Domschke Angelika*
Gorman Rob*
Hagmann Peter
Heggen Kristin*
Lally John*
Liphardt Bernd*

Lipscomb Lance*
Mahieu Frans
McKenney Curt
Meier Kristina
Minno George*
Mueller Robert Karl*
Quinn Michael*
Raheja MK
Vogt Juergen*
Zhou Jian*

*) Signifies present at meeting

Legend

I. Open issues from the March 2006 Meeting	p. 2
II. New Action Items	p. 3
III. Foreign Filing Decisions	p. 3
IV. PCT: Entering of National Phase	p. 4
V. EP Patents allowed	p. 4
VI. Maintenance Decisions	p. 4-6
VII. DiLens Patent Applications not transferred to EyeSense AG	p. 7
Annex 1 – CV Foreign Filing Standard Country Lists	p. 8

Summary

Attached is a summary of the June 2nd 2006 IPSC Meeting.

Remaining IPSC meeting dates 2006:

- Friday, September 1, 2006
- Friday, December 1, 2006

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

I. Open Issues/Results from March 2006 Meeting

ACTION ITEM	Responsible	Result
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

II: New Action items

ACTION ITEM	Responsible	Result
1. I A S		
2. I		
3. t		02/2006
4. I		02/2006
5. I		02/2006
6. I		
7. I		
8. I		02/2006

III. Foreign filing Decisions

Case First Filing	Key Term / Inventor(s)	Filing Decision (Actual Filings)
CL/V-34 13.10.20		Ianu PCT)
LP/V-34 16.11.20		36 PCT, AR, TH,
LP/V-34 16.11.20		36 PCT, AR, TH,
LP/V-34 16.11.20		36 PCT, AR, TH,
CL/V-34 24.11.20		Ianu PCT)
CL/V-34 14.12.20		PCT)

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

IV. PCT National/Regional Phase Entry Decision

Case	Key Term / Inventor(s)	Entering Decision
CLV-338		on postponed Quarter ig ction Item 1
CLV-339		on postponed Quarter ig ction Item 1

V. EP Patents Allowed: Decision on Validation in EPC Contracting States

Case	Key Term / Inventors	Validation Decision
CLV-324		
CLV-319		
CLV-318		
CLV-322		
CLV-315		
		FR, DE, GB, IT

VI. Maintenance Decisions

Provisional Decisions:

In cases for which a "provisional decision" has been taken during an IPSC Meeting, two weeks are provided for reviewing such a "provisional decision". If the responsible IPSC member wants to amend a provisional decision, please inform Rob Gorman (cc: Robert Karl Mueller) accordingly.

In the absence of instructions for amending a "provisional decision", the provisional decision becomes permanent and any measures for implementation of the decision may be executed.

Case No	Decision	Reason Action Item
LPV-168		
LPV-174		
LPV-319		
LPV-31		

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

CLV-169		
CLV-169		
CLV-174		
CLV-174		
CLV-179	ABD (provisional decision)	New Action Item No. 2
CLV-17	R to (DE, GB, IE, US) (ABD FR, JP)	
CLV-18	R to (US only) (provisional decision)	New Action Item No. 3
CLV-18	M - (CV-7)	
CLV-19	M - (CV-7, -CA)	
CLV-19	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-20	M - (DE, US)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-21	M - (DE only)	
CLV-21	M - (CV-7, -CA)	
CLV-21	M - (CV-7, -CA)	
CLV-21	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30	M - (CV-7, +NO, +ES, +SE)	
CLV-30	M - (CV-7, -CA)	
CLV-30	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30	M - (DE only)	
CLV-30	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30880/CGV 2112	M - (CV-7, -CA)	
CLV-308	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-312	M - (CV-7)	
CLV-313	M - (CV-7, +AR, +IE, +ES, +SE, +TW)	
CLV-313	M - (CV-7, -CA)	
CLV-313	M - (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CLV-313	M - (CV-7, +NO, +ES, +SE)	
CLV-316	M - (CV-7, +NO, +ES, +SE)	
CLV-317	M - (GB, JP, MX, US)	
CLV-317	M - all	
CLV-317	M - (CV-7, -CA)	
CLV-317	M - (AR, BR, CA, MY)	
CLV-317	R - (US only) (ABD EP) (provisional decision)	New Action Item No. 7

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

CL/V-31	R – (US only) (ABD EP, JP) (provisional decision)	New Action Item No. 7
CL/V-31	R – (US only) (ABD EP, JP) (provisional decision)	New Action Item No. 7
CL/V-31	ABD (provisional decision)	New Action Item No. 8
CL/V-31	ABD (provisional decision)	New Action Item No. 8
CL/V-31	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CL/V-31	M – (CV-7, -CA)	
CL/V-31	M – (LNS-23)	
CL/V-31	M – (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CL/V-31	M – (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CL/V-31	M – (CV-7, +NO)	
CL/V-31	M – (CV-7)	
CL/V-31	M – (CV-7, -CA)	
CL/V-32	M – (LNS-23)	
CL/V-32	M – (CV-7)	
CL/V-32	M – (CV-7)	
CL/V-32	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CL/V-32	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CL/V-32	M – (CV-7)	
CL/V-32	M – (CV-7)	
CL/V-32	M – (EP, US)	
CL/V-32	M – (EP, US)	
SUN-31	M – (CV-7, -CA)	Galin

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

VII. DiLens Patent Applications not transferred to EyeSense AG

Internal Case CLN	Priority Date	Title/Subject Matter	Status
321			DEL 1/02004/024035
325			
329			
329			
326			

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

ANNEX 1 - CIBA Vision Foreign Filing Standard Country Lists (last revised Nov. 30, 2005)

[illegible]

⁷ Country can be designated in a PCT patent application as of November 2005

*) PCT will enter into force for Malaysia on August 16, 2006

Minutes of the Q2 2007 IPSC Meeting
Confidential



Date : June 21, 2007

Subject : CIBA Vision Intellectual Property Steering Committee
Q1 2007 Meeting – June 7, 2007

Distribution

Aziz Tariq
Bassett Walt*)
Bielefeldt Florian
Brayley Ann
Forman Jeff
Gorman Rob*)
Hagmann Peter
Hu Sheng
Lipscomb Lance
Mallari Pamela*)

Martin Martha*)
McKenney Curt*)
Meece Scott
Minno George
Raheja MK*)
Vogt Juergen*)
Winterton Lynn*) (R.Scott attended for Lynn)
Zhou Jian*)

*) Signifies present at meeting

Legend

1A.	Open issues from the Q1 2007 IPSC Meeting	p. 2
1B.	New Action Items	p. 2-3
2.	Maintenance Issues	
2.1	Foreign Filing Decisions	p. 3
2.2	PCT: Entering of National/Regional Phase	p. 4
2.3	EP Patents allowed	p. 4
2.4	Maintenance Decisions	p. 5-6
Annex 1 – CV Foreign Filing Standard Country Lists		p. 7

Summary

Attached is a summary of the June 7, 2007 IPSC Meeting.

Further IPSC meeting dates 2007:

- Thursday, September 6, 2007
- Thursday, December 6, 2007

Minutes of the Q2 2007 IPSC Meeting
Confidential

1A. Open Issues/Results from last IPSC Meeting

	ACTION ITEM	Responsible	Status / Due date
1			
2			
3			
4			
5			
6			
7			
8			
9			

1B. New Action Items

	ACTION ITEM	Responsible	Status / Due date
1			
2			
3			
4			
5			
6			

Minutes of the Q2 2007 IPSC Meeting
Confidential

8	
9	
1	AU,
1	
1	
1	

2. Maintenance Issues

2.1 Foreign Filings

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
			+
			+
			S
			S
			S
			S

Minutes of the Q2 2007 IPSC Meeting

Confidential

2.2 PCT: Entering of National/Regional Phase

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
341			
341			
341			
342			
342			
34			
34			
J. Hagemann, G. Lassig, K. Biele			

2.3 EP Patents Allowed (Decisions on the Validation of the Patent in EPC Contracting States)

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
Lens Care			
321			

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
Contact Lens			
311			
32			
32			

Minutes of the Q2 2007 IPSC Meeting

Confidential

2.4 Maintenance Decisions

Provisional Decisions: 2 weeks are provided for reviewing "provisional decisions". If the responsible IPSC member wants to amend a provisional decision, please inform Rob Gorman (cc: Florian Bielefeldt) accordingly. In the absence of instructions for amending a "provisional decision", the provisional decision becomes final and any measures for implementation of the decision may be executed.

Case	Keyword	Decision	Reason
Lens Care			
168			
174			U, TW (prov.) tem 10
313			
317			

Case	Keyword	Decision	Reason
Con			
169		M - (CV-7, -CA, -US)	
184		M - (CV-7)	
191		M - (CV-7, -CA)	Action Item 11
30880/CGV 2112	Silicone Containing	M - (CV-7, -CA)	
313		M - (CV-7, +NO, +ES, +SE)	
303		M - (CV-7, +NO, +ES, +SE)	
313		M - (US only)	
313		M - (CV-7, +AR, +IE, +ES, +SE, +TW)	
313		M - (CV-7, -CA)	
318		M - (CV-7, -CA)	
322		M - (LNS-23)	
322		M - (CV-7)	
203		M - (CV-7, -CA)	
203		M - (CV-7, -CA)	
203		M - (CV-7, -CA)	
203		M - (CV-7, -CA)	
203		M - (CV-7, -CA)	
203		M - (CV-7, -CA)	
212		M - (CV-7, -CA)	
212		M - (CV-7, -CA)	
312		M - (CV-7)	
317		M - (US only)	
318		M - (LNS-23)	
174		M - (CV-7, -CA)	
203		R - (US Only)	ABD DE
316		M - (CV-7, +NO, +ES, +SE)	
317		M - (GB, JP, MX, US)	Action Item 12

Minutes of the Q2 2007 IPSC Meeting

Confidential

Case	Keyword	Decision	Reason
		M – (US only)	
		M – (US only)	
		M – (CV-7)	
		M – (DE, GB, IE, US)	
		M – (US only)	
		M – (US, JP, DE, GB, FR, IE)	
		M – (DE only)	
		M – (US, JP, DE, GB, FR, IE)	
		M – (CV-7, -CA)	
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (US, JP, DE, GB, IE)	ABD FR
		ABD (Prov)	Action Item 13
		M – (US, JP, DE, GB, IE)	
		M – (CV-7, +NO)	
		M – (EP, JP, US)	
		M – (CV Manu, -MY)	
		M – (US only)	
		M – (CV-7, -CA)	
		M – (US only)	
		M – (US only)	
		M – (CV-7)	
		M – (CV-7)	
		M – (CV-7)	
		M – (CV-7, +AU)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US, JP, DE, GB, IE)	
		M – (US only)	
		M – (EP, US)	
		M – (EP, US)	
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (IE, US)	ABD FR, DE, GB, JP
		M – (US, JP, DE, GB, FR, IE)	
		M – (CV-7, -CA)	Action Item 5

Minutes of the Q2 2007 IPSC Meeting
Confidential

ANNEX 1 - CIBA Vision Standard Country Lists (last revised Nov. 30, 2005)

[illegible]

designates: country can be designated in a PCT patent application (status as of August 16, 2006)

Decision List

for abandonment

Section
CIBA Vision (Prio JAN-MAR)

CL/V -30880/CGV 2112

Page 1 of 2

Priority 30.03.1999 USA

Patent Specialist LIP

Section Subgroup LNS

Inventor(s) T. Hirt
T. HollandJ. Schremmer
D. Lohmann

Contracts 99/02/ Contract active maint. relevant

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS
☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee Ind.	Costs CHF
<input type="checkbox"/> Europe	A	EuPCT	pending	03/2003	2020	NOV	4	593
Austria	A	EuPCT	pending		2020	NOV		
Belgium	A	EuPCT	pending		2020	NOV		
Cyprus	A	EuPCT	pending		2020	NOV		
Denmark	A	EuPCT	pending		2020	NOV		
Finland	A	EuPCT	pending		2020	NOV		
France	A	EuPCT	pending		2020	NOV		
Germany	A	EuPCT	pending		2020	NOV		
Great Britain	A	EuPCT	pending		2020	NOV		
Greece	A	EuPCT	pending		2020	NOV		
Ireland	A	EuPCT	pending		2020	NOV		
Italy	A	EuPCT	pending		2020	NOV		
Luxemburg	A	EuPCT	pending		2020	NOV		
Monaco	A	EuPCT	pending		2020	NOV		
Netherlands	A	EuPCT	pending		2020	NOV		
Portugal	A	EuPCT	pending		2020	NOV		
Spain	A	EuPCT	pending		2020	NOV		
Sweden	A	EuPCT	pending		2020	NOV		
Switzerland	A	EuPCT	pending		2020	NOV		
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 593

Costs until expiry 21,745

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	abandoned 2001
USA	P1		abandoned 2000

26.04.2002

Section
CIBA Vision (Prio JAN-MAR)

Decision List

for abandonment

CL/V -30880/CGV 2112

Page 2 of 2

No Decision

Country	Ident. code	Fil.proc.	Remarks
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Decision date:

Signature:
(according to section regulations)

Patsys

Decision List

for abandonment

E2

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

Priority 30.03.1999 USA
Patent Specialist LIP
Section Subgroup LNS

Inventor(s) T. Hirt
T. Holland

J. Schremmer
D. Lohmann

Contracts 99/02/ Contract active maint. relevant

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS

Products, compounds, projects

~~CLV -30880~~

Invention category Product

Utility code 4 BIO

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> Europe	A	EuPCT	pending	03/2005	2020	NOV	6	1105
Austria	A	EuPCT	pending		2020	NOA		
Belgium	A	EuPCT	pending		2020	NOV		
Cyprus	A	EuPCT	pending		2020	NOV		
Denmark	A	EuPCT	pending		2020	NOV		
Finland	A	EuPCT	pending		2020	NOV		
France	A	EuPCT	pending		2020	NOV		
Germany	A	EuPCT	pending		2020	NOV		
Great Britain	A	EuPCT	pending		2020	NOV		
Greece	A	EuPCT	pending		2020	NOV		
Ireland	A	EuPCT	pending		2020	NOV		
Italy	A	EuPCT	pending		2020	NOV		
Luxemburg	A	EuPCT	pending		2020	NOV		
Monaco	A	EuPCT	pending		2020	NOV		
Netherlands	A	EuPCT	pending		2020	NOV		
Portugal	A	EuPCT	pending		2020	NOV		
Spain	A	EuPCT	pending		2020	NOV		
Sweden	A	EuPCT	pending		2020	NOV		
Switzerland	A	EuPCT	pending		2020	NOV		
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 1,105
Costs until expiry 21,171

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

Patsys

Decision List
for abandonment

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001 abandoned 2000
USA	P1		expired 2000
USA	P1/PROV		

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Decision date:

Signature:
(according to section regulations)

Intellectual Property Steering Committee (IPSC) View

CIBA Vision Corporation

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : XXXXXXXXXX U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
---	---

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure) wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment; B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group; Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group; (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy; L1, L2 and L3 are each independently of the other a linking group; p1 and q1 are each independently of the other an integer from 1 to 12; and either t is 0 and p and q are each independently of the other an integer from 1 to 25; or t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

Decision List for abandonment

E3

28.04.2005
Page 64/147

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

Priority 30.03.1999 USA
Attorney RKM
Section Subgroup LNS
Inventor(s) T. Hirt J. Schremmer
T. Holland D. Lohmann
Contracts 99/02/ Contract active maint. relevant

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS

Products, compounds, projects

Invention category Product

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> France	A	EuPCT	granted	03/2006	2020	NOV	7	208
<input type="checkbox"/> Germany	A	EuPCT	granted	03/2006	2020	NOV	7	277
<input type="checkbox"/> Great Britain	A	EuPCT	granted	03/2006	2020	NOV	7	204
<input type="checkbox"/> Italy	A	EuPCT	granted	03/2006	2020	NOV	7	198
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 887

Costs until expiry 44,234

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001
USA	P1		abandoned 2000
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007



Decision List

for abandonment


Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

Decision date:

Signature:
(according to section regulations)

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials :  U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
---	---


U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure)
 wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein
 A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment;
 B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group;
 Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group;
 (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy;
 L1, L2 and L3 are each independently of the other a linking group;
 p1 and q1 are each independently of the other an integer from 1 to 12; and either
 t is 0 and p and q are each independently of the other an integer from 1 to 25; or
 t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: 06/02/2004 - MAINTAIN LNS B6
June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains



Decision List
for abandonment

27.03.2006
Page 52/136

E4

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

Priority 30.03.1999 USA
Attorney RKM
Section Subgroup LNS

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS

Inventor(s) T. Hirt J. Schremmer
T. Holland D. Lohmann
Contracts 99/02/ Contract active maint. relevant

Products, compounds, projects

Invention category Product

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> France	A	EuPCT	granted	03/2007	2020	NOV	8	209
<input type="checkbox"/> Germany	A	EuPCT	granted	03/2007	2020	NOV	8	372
<input type="checkbox"/> Great Britain	A	EuPCT	granted	03/2007	2020	NOV	8	248
<input type="checkbox"/> Italy	A	EuPCT	granted	03/2007	2020	NOV	8	272
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 1,101
Costs until expiry 43,879


'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001
USA	P1		abandoned 2000
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007



Decision List

for abandonment

27.03.2006
Page 53/136

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

Decision date:

Signature:
(according to section regulations)

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : [REDACTED] U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
---	--

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure)
wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment;
B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group;
Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group;
(alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy;
L1, L2 and L3 are each independently of the other a linking group;
p1 and q1 are each independently of the other an integer from 1 to 12; and either t is 0 and p and q are each independently of the other an integer from 1 to 25; or t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: May 25, 2005 IPSC Comments: Maintain (JWC). 06/02/2004 - MAINTAIN
LNS B6

June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

PATENT DECISION LIST

14 - May - 2007

Family 30880

Original Reference **CGV 2112** Keywords **Silicone Containing**
BULK MATERIAL WITH WETTABLE SURFACE WITHOUT COATING; DANGLING CHAINS
 Internal Title
 Business Unit **CV** Global Attorney **Zhou (JZ)**
 Business Line **CL** EP Attorney **Bielefeldt (FB)**
 Invention Category **Material** US Attorney **Zhou (JZ)**
 Inventors **Hirt Thomas**
Schremmer Jacalyn Mary
Holland Troy Vernon
Lohmann Dieter
 First Priority **United States Of America (NP) - 30 Mar 1999 - 09/280510**

keep?

Fees Due

Country	Status	Past costs CHF	Next annuity	Cost CHF	Cost until expiry CHF
CLV -30880A/CGV FR-EPT France	Grant	1,313	31-MAR-2006 for 07	244	8,043
CLV -30880A/CGV DE-EPT Germany	Grant	4,243	31-MAR-2006 for 07	292	20,425
CLV -30880A/CGV GB-EPT United Kingdom	Grant	642	28-MAR-2008 for 09	317	7,293
Total :		6,198		853	35,761

In Force - No fees due

Country	Status
CLV -30880A/CGV IT-EPT Italy	Grant
CLV -30880A/CGV JP-PCT Japan	Publication of application
CLV -30880A/CGV US-NP United States Of America	Filed

Abandoned - not in force

Country	Status
CLV -30880A/CGV WO-PCT International Procedure	Abandoned
CLV -30880/P1/CGV US-NP United States Of America	Abandoned Priority Application
CLV -30880/P1/PROV/CGV US-PSP United States Of America	Terminated

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : XXXXXXXXXX U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
---	--

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure)
 wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein
 A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment;
 B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group;
 Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group;
 (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy;
 L1, L2 and L3 are each independently of the other a linking group;
 p1 and q1 are each independently of the other an integer from 1 to 12; and either
 t is 0 and p and q are each independently of the other an integer from 1 to 25; or
 t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: May 25, 2005 IPSC Comments: Maintain (JWC). 06/02/2004 - MAINTAIN
LNS B6
June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

CIBAVision®

A Novartis Company

CIBA Vision Corporation

Patent Department

11460 Johns Creek Parkway

Duluth, GA 30097-1556

*Change filing
receipt*

F1

FAX MESSAGE

DATE: May 3, 2000

TO: Betty Robinson
US PTO

FROM: Ann Brayley
CIBA Vision Patent Department
Voice: 678-415-3672 Fax: 678-415-3068

Dear Ms. Robinson,

Please see attachment. Our Docket CL/V-30880/P1/CGV2112 carries an application number of 09/280,510, (as indicated on the Filing Receipt) not 09/208,510. Please send a corrected Decision on Petition.

Thank you.

TOTAL NUMBER OF PAGES (including coversheet) 2

The information contained in this facsimile message is legally privileged and confidential information, intended only for use by the addressee listed above. If you have received this message in error, you are hereby notified that any disseminating, distributing or copying of this information is strictly prohibited. Further, if you have received this information in error, we request that you contact Ann Brayley 770-418-3672. We appreciate your cooperation.


April 11, 2000

703.385 9822

Page # 4

Melvyn M Kassenoff
Novartis Corporation
Patent and Trademark Dept
564 Morris Avenue
Summit, NJ 07904-1027

RJG



In re Application of:
Hirt, etal.

Application No.: 09/208,510

Filed: March 30, 1999

Attorney Docket No.: CLV-30880/P1CGV2112

DECISION ON PETITION

This is a decision on your petition received in the Patent and Trademark Office on March 13, 2000 treated as a petition under 37 CFR 1.53(b)(2)(ii) to convert the above identified application to a Provisional application under 35 U.S.C. 111 (b) and 37 CFR 1.53(b)(2).


The petition is granted.

The application will be processed in the Office of Initial Patent Examination (OIPE) as a Provisional application under 35 U.S.C. 111(b) and 37 CFR 1.53(b)(2), including the assignment of a new Provisional application number.

The Provisional application serial number is 60/183,047 the filing receipt for the Provisional application number will be communicated to applicant by OIPE in due course.

A handwritten signature in cursive script, appearing to read "Betty L. Robinson".

Betty L. Robinson, Program Assistant
Office of Initial Patent Examination
(703) 308-0910



APRIL 20, 2000

Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Our Ref. Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/P1CVG2112
Application No. 09/208,510

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☒ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

26. APR. 2000

ERSTERFASSUNG	10.000
ZWEITERFASSUNG	10.000

27. APR. 2000

Very truly yours,

Robert J. Gorman

Robert J. Gorman
678-415-4389

Please note that the
correct Application-
Nr. is 09/280510 and
not 04/208510!

Regards

Frau T. Oswald
Patent & Trademarks
S - 503.703.04.55 31

T. Oswald

April 11, 2000


703-305 9822

Washington, D.C. 20231

Page # 4

Melvyn M Kassenoff
Novartis Corporation
Patent and Trademark Dept
564 Morris Avenue
Summit, NJ 07904-1027

RJG



In re Application of:
Hirt, et al.

Application No.: 09/208,510 —

Filed: March 30, 1999

Attorney Docket No: CLV-30880/P1CGV2112

DECISION ON PETITION


This is a decision on your petition received in the Patent and Trademark Office on March 13, 2000 treated as a petition under 37 CFR 1.53(b)(2)(ii) to convert the above identified application to a Provisional application under 35 U.S.C. 111 (b) and 37 CFR 1.53(b)(2).

The petition is granted.

The application will be processed in the Office of Initial Patent Examination (OIPE) as a Provisional application under 35 U.S.C. 111(b) and 37 CFR 1.53(b)(2), including the assignment of a new Provisional application number.

The Provisional application serial number is 60/183,047 the filing receipt for the Provisional application number will be communicated to applicant by OIPE in due course.

Betty L. Robinson, Program Assistant
Office of Initial Patent Examination
(703) 308-0910



- 7. Mai 1999

Patent Department
Telephone: 770-418-3672
Fax: 770-418-3068

APPL.	M/D	F/L	PS/TS	
Kopien:				

April 27, 1999

DUE DATE:

Dr. J. Dietz
Novartis Services AG
Patent and Trademark Dept.
Lichtstrasse 35
CH-4002 Basel

Re: Patent Application
Application No.: 09/280,510
Case: CL/V-30880/P1/CGV2112

Ladies and Gentlemen:

To keep you advised of the prosecution of the above-indicated case, we are enclosing

- () copy of Blue Filing Receipt -
- () copy of Application Transmittal Letter, Specification, Drawings, Basel casecard, Diskette
- () copy of Conversion of Non-provisional to Provisional Application Transmittal
- () copy of PTO Form 903 - Notification of Acceptance of Application (PCT)
- (x) copy of Post Card received from PTO
- () copy of 1A Assignment and Transmittal
- () copy of Notice of Allowance and Issue Fee Due w/supporting documents & allowed claims
- () copy of Issue Fee as submitted to PTO
- () copy of Amendment dated 4/19/99
- () copy of Petition for Extension of Time
- () copy of Notice of Appeal dated
- () copy of Office action dated
- () copy of Information Disclosure Transmittal with PTO Form 1449 only
- () copy of Notice of Missing Parts
- () copy of Response to Notice of Missing Parts
- () copy of Claim of Priority, dated
- () copy of other:

[Handwritten signature and initials]

NOVARTIS CORPORATION

[Handwritten signature of Ann Brayley]

Ann Brayley
Patent Administrative Assistant

Case No. CGV 2112

Application/Serial No. _____



Mailing Date: 3/30/99

Due Date: _____

The Patent & Trademark Office acknowledges, and has stamped hereon the date of receipt of the items checked below:

- ☐ Amendment - Fee \$ APP 1999
- ☐ Appeal Brief - Fee \$ _____
- ☒ Application Filing Papers - Fee \$ 8760
- ☐ PCT national phase entry
- ☐ Provisional Application
- ☐ Assignment Recordation - Fee \$ _____
- ☐ Associate Power of Attorney
- ☐ Claim of Priority
- ☐ Certified Copy(ies)
- ☒ Declaration and Power of Attorney
- ☐ Declaration ☐ Rule 131 ☐ Rule 132
- ☐ Foreign Filing license request
- ☐ Formal Drawings
- ☐ Information Disclosure Statement - Fee \$ _____
- ☐ Issue Fee Transmittal - Fee \$ _____
- ☐ Letter/Response
- ☐ Notice of Appeal - Fee \$ _____
- ☐ Petition for _____ - Fee \$ _____
- ☐ Petition for extension of time - Fee \$ _____
- ☐ Reply Brief
- ☐ Request for Oral Hearing - Fee \$ _____
- ☐ Request for Certification of Correction - Fee \$ _____
- ☐ _____

MUL



DOCKETED FOR May 30, 1999

21. Mai 1999

APPL. M/D F/L PS/TS

Kopien:

May 19, 1999

Patent Department
Telephone: 770-418-3672
Fax: 770-418-3068

DUE DATE:

Dr. J. Dietz
Novartis Services AG
Patent and Trademark Dept.
Lichtstrasse 35
CH-4002 Basel

Re: Patent Application
Application No.: 09/280,510
Case: CL/V-30880/P1/CGV2112

Ladies and Gentlemen:

To keep you advised of the prosecution of the above-indicated case, we are enclosing

- (x) copy of Blue Filing Receipt
- () copy of Application Transmittal Letter, drawings, Form 1449
- () copy of Conversion of Non-provisional to Provisional Application Transmittal
- () copy of PTO Form 903 - Notification of Acceptance of Application (PCT)
- () copy of Post Card received from PTO
- () copy of 1A Assignment and Transmittal
- () copy of Notice of Allowance and Issue Fee Due w/supporting documents & allowed claims
- () copy of Issue Fee as submitted to PTO
- () copy of Amendment dated
- () copy of Petition for Extension of Time
- () copy of Notice of Appeal dated
- () copy of Office action dated
- () copy of Information Disclosure Transmittal with PTO Form 1449 only
- () copy of Notice of Missing Parts
- () copy of Response to Notice of Missing Parts
- () copy of Claim of Priority, dated
- () copy of other:

NOVARTIS CORPORATION

Ann Brayley
Ann Brayley
Patent Administrative Assistant

J. Dietz
A. Hiss
✓ B. Hiss
W. Schmid
G. von Sp.

25. Mai 1999

ERSTERFASSUNG Visum: *C. Hiss*
ZWEITERFASSUNG Visum: *C. Hiss*



APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/280,510	03/30/99 ✓	1714	\$760.00	CGV2112	0	17	1

001095

MELVYN M KASSENOFF
NOVARTIS CORPORATION
PATENT AND TRADEMARK DEPT
564 MORRIS AVENUE
SUMMIT NJ 07901-1027

*CL/V-30880/P1/CGV2112**MUL**CV*

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)


THOMAS HIRT, ATLANTA, GA; TROY VERNON HOLLAND, SUWANNE, GA; DIETER LOHMANN, MUNCHENSTEIN, SWITZERLAND.

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 04/15/99

TITLE

ORGANIC COMPOUNDS

PRELIMINARY CLASS: 523



DATA ENTRY BY: ROBINSON, CARMENCITA TEAM: 02 DATE: 04/15/99



(see reverse)

F2



DATE: March 14, 2000

Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION
ONLY

Re: CL/V-30080/A/CGV2112
Application No.

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☒ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENTRY

F3

CASE CV. 30880/A/CGV2112 APPLICATION NO. _____

PRESENT DOCKET DATE 3/29/00

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

<input type="checkbox"/> AMENDMENT/RESPONSE	<input type="checkbox"/> DRAWINGS
<input type="checkbox"/> RESPONSE TO FINAL REJECTION	<input type="checkbox"/> PRELIMINARY AMENDMENT
<input type="checkbox"/> INFORMATION DISCLOSURE STATEMENT	<input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE	<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE
<input type="checkbox"/> NOTICE OF APPEAL \$300	<input type="checkbox"/> ISSUE FEE \$1210
<input type="checkbox"/> APPEAL BRIEF \$300	<input type="checkbox"/> PTO-1449 FORM
<input type="checkbox"/> ASSIGNMENT RECORDATION \$40	<input type="checkbox"/> DIVISION CHECK
<input type="checkbox"/> CLAIM OF PRIORITY	<input type="checkbox"/> REQUEST FOR CORRECTED FILING RECEIPT
<input type="checkbox"/> DECLARATION - MISSING PARTS/MISSING REQUIREMENTS \$130	<input type="checkbox"/> REQUEST FOR CERTIFICATE OF CORRECTION
<input type="checkbox"/> EXTENSIONS OF TIME	
<input type="checkbox"/> 1 st - 110 <input type="checkbox"/> 2 nd - \$380 <input type="checkbox"/> 3 rd - \$870 <input type="checkbox"/>	
<input checked="" type="checkbox"/> APPLICATION*	<input type="checkbox"/> PCT <input type="checkbox"/> PROVISIONAL - \$150 <input type="checkbox"/> PETITION TO CONVERT - \$50
FEE \$ <u>760</u> <input type="checkbox"/> CIP <input type="checkbox"/> CONTINUATION <input type="checkbox"/> DIVISIONAL <input type="checkbox"/> FILED "A" (Old "R")	

OTHER _____

ATTORNEY: RJG | DATE: 3/14/00

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: March 29, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☒ Other Document(s) Serial Card

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F5



A Novartis Company

DATE: May 31, 2000

Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☒ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENTRY

F6

CASE CL/V. 30880/A/CGV2112

APPLICATION NO. 09/0
525, 158

PRESENT DOCKET DATE 7/16/08

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

☐ AMENDMENT/RESPONSE

☐ DRAWINGS

☐ RESPONSE TO FINAL REJECTION

☐ PRELIMINARY AMENDMENT

☐ INFORMATION DISCLOSURE
STATEMENT

☐ SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

☐ (LATE FEE) - \$240

☐ NO FEE

☐ (LATE FEE) - \$240

☐ NO FEE

☐ NOTICE OF APPEAL

\$300

☐ ISSUE FEE

\$1210

☐ APPEAL BRIEF

\$300

☐ PTO-1449 FORM

☐ ASSIGNMENT RECORDATION

\$40

☐ DIVISION CHECK

☐ CLAIM OF PRIORITY

☐ REQUEST FOR CORRECTED FILING
RECEIPT

☒ DECLARATION - \$130
MISSING PARTS/MISSING REQUIREMENTS

☐ REQUEST FOR CERTIFICATE OF
CORRECTION

☐ EXTENSIONS OF TIME

☐ 1st - 110

☐ 2nd - \$380

☐ 3rd - \$870

☐

☐ APPLICATION*

☐ PCT

☐ PROVISIONAL - \$150

☐ PETITION TO CONVERT - \$50

FEE \$ _____ ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A"
(Old "R")

OTHER _____

ATTORNEY: R J G | DATE: 6/2/08

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____

F7



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: June 13, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☒ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F8



DATE: July 14, 2000

Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☒ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389



Dr. Bernd Liphardt
Patent Attorney

Novartis AG
Corporate Intellectual Property
Patent & Trademark Department CH
CH-4002 Basel
Switzerland
Tel: +41 61 324 34 95
Fax: +41 61 322 75 32

F9

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155

June 27, 2000

Your Ref:

Our Ref:
LIP


Information Disclosure Statement

U.S. Patent Application No: 09/525,158
Case: CL/V-30880/CGV 2112

Ladies and Gentlemen

I. References (and English language equivalents thereof)

- [1] US-A-5,219,965 (Valinth Jr et al.)
- [2] US-A-5,364,918 (Valinth Jr et al.)
- [3] US-A-5,589,563 (Ward et al.)



II. Related pending U.S. Patent Applications

U.S. Serial No. 09/217,238 , our Case CL/V-30764/A/CGV 2066

Please find enclosed herewith:

- ☒ copy of the references mentioned above and English language equivalents or abstracts thereof

Yours faithfully
Novartis AG

Dr. Bernd Liphardt
Patent Attorney

Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer
Health, Animal Health

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155

TELEFAX

From: +41 61 322 75 32
To: 0001 678 415 3068
Total pages: 1

June 30, 2000

Your Ref:

Our Ref:
LIP

Information Disclosure Statement

U.S. Patent Application No: 09/525,158
Case: CL/V-30880/A/CGV 2112

Ladies and Gentlemen

I. References (and English language equivalents thereof)

- [1] WO-A-97/00274 (our Case CL/V-20486/A/ERT 7)
- [2] EP-A-291,452 (equivalent to [3], our case CL/V-16453+/CGV 1274)
- [3] US-A-4,837,289 (Mueller et al.), equivalent to [2])
- [4] US-A-5,760,100 (Nicolsòn et al.) (CL/V-20676/P1/CGV 1764, JUMP)
- [5] WO-A-97/49740 (CL/V-20926/A/CGV 1866)
- [6] WO-A-96/31791 (CL/V-20395/A, Betacon)
- [7] EP-A-330,616 (CL/V-16918+/CGV 1332)

Please find enclosed herewith:

- ☒ copy of the references (by confirmation mail)
- ☒ copy of PCT/EP Search Report showing date of the Report (by conf. mail)
- ☒ copy of equivalency list issued by the EPO

Yours faithfully
Novartis AG



Dr. Bernd Liphardt
Patent Attorney



Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer
Health, Animal Health

F11

CASE CC/V-30880/A/CGV2112 APPLICATION NO. _____

PRESENT DOCKET DATE 6/14/00

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

<input type="checkbox"/> AMENDMENT/RESPONSE	<input type="checkbox"/> DRAWINGS
<input type="checkbox"/> RESPONSE TO FINAL REJECTION	<input type="checkbox"/> PRELIMINARY AMENDMENT
<input checked="" type="checkbox"/> INFORMATION DISCLOSURE STATEMENT	<input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE	<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE
<input type="checkbox"/> NOTICE OF APPEAL \$300	<input type="checkbox"/> ISSUE FEE \$1210
<input type="checkbox"/> APPEAL BRIEF \$300	<input type="checkbox"/> PTO-1449 FORM
<input type="checkbox"/> ASSIGNMENT RECORDATION \$40	<input type="checkbox"/> DIVISION CHECK
<input type="checkbox"/> CLAIM OF PRIORITY	<input type="checkbox"/> REQUEST FOR CORRECTED FILING RECEIPT
<input type="checkbox"/> DECLARATION - MISSING PARTS/MISSING REQUIREMENTS \$130	<input type="checkbox"/> REQUEST FOR CERTIFICATE OF CORRECTION
<input type="checkbox"/> EXTENSIONS OF TIME	
<input type="checkbox"/> 1 st - 110 <input type="checkbox"/> 2 nd - \$380 <input type="checkbox"/> 3 rd - \$870 <input type="checkbox"/>	
<input type="checkbox"/> APPLICATION* <input type="checkbox"/> PCT <input type="checkbox"/> PROVISIONAL - \$150 <input type="checkbox"/> PETITION TO CONVERT - \$50	

FEE \$ _____ ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A" (Old "R")

OTHER _____

ATTORNEY: RTG | DATE: 8/30/00

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____

F12



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: August 31, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556
Our Ref.

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☒ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F13

Memorandum



A Novartis Company

Date: March 28, 2001

To: Jackie Schremmer

From: Rob Gorman

Subject: CL/V-30880A/CGV2112
Serial No. 09/525,158

Patent Attorney
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
rob.gorman@cibavision.novartis.com
phone 678 415-4389
fax 678-415-3018

We have received a response from the U.S. Patent and Trademark Office (an "Office action") in the above-identified patent application which names you as an inventor. A copy of this Office action is enclosed for your review.

We are sending you a copy of this Office action for two reasons. First, we wish to keep you informed of the progress in your case. Second, we wish to have your input on the differences between your invention (as defined by the claims) and the prior art (other patents and publications) used against us by the Patent Examiner.

We also wish to remind you of the CONTINUING DUTY to inform the Patent Office of any prior art references (patents, publications, etc.) which may be deemed relevant to the patentability of the claimed invention in the pending patent application. PLEASE SEND US COPIES OF ANY POTENTIALLY RELEVANT PRIOR ART WHICH YOU HAVE NOT ALREADY SENT.

With respect to your comments in distinguishing the prior art, please focus on the rejections in the Office action which discuss 35 U.S.C. 102 (novelty) and 35 U.S.C. 103 (obviousness). If you have any questions, or would like to discuss the differences between your invention and the prior art, please call.

In order to meet the deadline for responding to this Office Action, we need to have your comments by **May 1, 2001**.

Thank you for your assistance.

F14



DATE: March 28, 2001

Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556
Our Ref.

DUE DATE: June 12, 2001

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880A/CGV2112
Application No.: 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☒ Paper(s) received from the PTO (Dated: 3/12/01)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Rob Gorman
(Signature)

Robert J. Gorman, Jr.
678-415-4389



Dr. Bernd Liphardt
Patent Attorney

Novartis AG
Corporate Intellectual Property
Patent & Trademark Department CH
CH-4002 Basel
Switzerland
Tel: +41 61 324 79 97
Fax: +41 61 322 75 32

F15

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155

TELEFAX


From: +41 61 322 75 32

To: 0001 678 415 3068

Total pages: 2

Your Ref:

May 22, 2001



U.S. Patent Application Serial No. 09/525,158 – Case CL/V-30880A/CGV2112

Dear Rob

Thank you for your letter of March 28, 2001 with the enclosed Office action.
Please find below our comments and proposals.

Regarding the restriction requirement under 35 U.S.C. 121, we agree to confirm the election of group I (claims 1 to 12).

Specification

- The terms (alk) and (alk') are different and relate to different formulas. (alk) (page 1, line 25) relates to formula (1), whereas (alk') (page 3, line 2) relates to formula 2. Accordingly, no amendment is deemed necessary.
- If acceptable under US practice, we suggest deleting the word "suitable" in the expression "a suitable salt" (page 9, lines 2-3).
- Please add the missing hydrogens in " $_3C$ " in line 5 of page 37.

Claim Objections

- In our view claim 4 is a perfect dependent claim. However, if there are rules or provisions we are unaware of, please feel free to rewrite the claim in independent form.
- As to claim 7 we propose to amend it as follows:
"An amphiphilic block copolymer according to claim 1, wherein B is a non-ionic segment selected from the group consisting of a polyoxyalkylene, polysaccharide, polypeptide, poly(vinylpyrrolidone), polyalkylacrylate, polymethacrylate, polyhydroxyalkylacrylate,

- polyhydroxymethacrylate, polyacyl alkylene imine, polyacryl amide, polyvinyl alcohol, polyvinyl ether and a polyol, or B is a polyionic segment selected from the group consisting of a polyallylammonium, polyethylencimine, polyvinylbenzyltrimethylammonium, polyaniline, sulfonated polyaniline, polypyrrole, polypyridine, polyacrylic acid, polymethacrylic acid, a polythiophene-acetic acid, a polystyrenesulfonic acid and a zwitterionic segment, or a salt thereof."
- Please deal with the additional informalities ("-NR-" in line 29 of claim 10 and "H (or CH₃" in claim 10 as proposed by the Examiner.

Regarding the claim rejections under 35 USC § 112:


- In the above-redrafted claim 7 the expression "a suitable salt" has been amended to "a salt" and the problems associated with the Markush language have been dealt with.
- In Claims 9 and 11 delete the phrase "for example".

As to the claim rejections under 35 USC § 102 we suggest to amend the second last line of claim 1 to


"r is 0 and p and q are each independently of the other an integer from 2 to 20; or", support for which can be found on page 2, line 20 of the specification.

The amendment is deemed to establish novelty over Meijs (US 5,981,615).

Yours very truly
Novartis AG



Dr. Bernd Liphardt
Patent AttorneyPatent Attorney



Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer Health,
Animal Health

filed 6.8.01

DOCKET NOTE/REPORT ENTRY

F16

CASE CL/V-30880A/CGV2112 APPLICATION NO. 09/525,158

PRESENT DOCKET DATE June 12, 2001

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

☒ AMENDMENT/RESPONSE

☐ DRAWINGS

☐ RESPONSE TO FINAL REJECTION

☐ PRELIMINARY AMENDMENT

☐ INFORMATION DISCLOSURE
STATEMENT

☐ SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

☐ (LATE FEE) - \$180

☐ NO FEE

☐ (LATE FEE) - \$180

☐ NO FEE

☐ NOTICE OF APPEAL

\$310

☐ ISSUE FEE

\$1240

☐ APPEAL BRIEF

\$310

☐ PTO-1449 FORM

☐ ASSIGNMENT RECORDATION

\$40

☐ DIVISION CHECK

☐ CLAIM OF PRIORITY

☐ REQUEST FOR CORRECTED FILING
RECEIPT

☐ DECLARATION -
MISSING PARTS/MISSING REQUIREMENTS

\$130

☐ REQUEST FOR CERTIFICATE OF
CORRECTION

☐ EXTENSIONS OF TIME

☐ 1st - 110

☐ 2nd - \$390

☐ 3rd - \$890

☐

☐ APPLICATION*

☐ PCT

☐ PROVISIONAL - \$150

☐ PETITION TO CONVERT - \$50

FEE \$ _____ ☐ CIP ☐ CONTINUATION

☐ DIVISIONAL

☐ FILED "A"
(Old "R")

OTHER _____

ATTORNEY: Richard G. Gant DATE: 6.8.01

* WITH BASLE FAX (On U.S. Originated Case Only)

F17

Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

June 11, 2001

**CIBA
Vision®**
A Novartis Company

Your Ref

Our Ref CIBA Vision Corporation
Legal Department

DUE DATE:

June 10, 2001

RESPONSE DATE:

11460 Johns Creek Parkway
Duluth, Georgia 30097-1556
FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112

Application No: 09/ 525, 158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☒ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENT.

F18

CASE CH/V- 30080/A/BV 2112

APPLICATION NO. 09/525, 158

PRESENT DOCKET DATE July 21, 2001

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

☒ AMENDMENT/RESPONSE

☐ DRAWINGS

☐ RESPONSE TO FINAL REJECTION

☐ PRELIMINARY AMENDMENT

☐ INFORMATION DISCLOSURE
STATEMENT

☐ SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

☐ (LATE FEE) - \$180

☐ NO FEE

☐ (LATE FEE) - \$180

☐ NO FEE

☐ NOTICE OF APPEAL

\$310

☐ ISSUE FEE

\$1240

☐ APPEAL BRIEF

\$310

☐ PTO-1449 FORM

☐ ASSIGNMENT RECORDATION

\$40

☐ DIVISION CHECK

☐ CLAIM OF PRIORITY

☐ REQUEST FOR CORRECTED FILING
RECEIPT

☐ DECLARATION -
MISSING PARTS/MISSING REQUIREMENTS

\$130

☐ REQUEST FOR CERTIFICATE OF
CORRECTION

☐ EXTENSIONS OF TIME

☐ 1st - 110

☐ 2nd - \$390

☐ 3rd - \$890

☐

☐ APPLICATION*

☐ PCT

☐ PROVISIONAL - \$150

☐ PETITION TO CONVERT - \$50

FEE \$

no fee

☐ CIP

☐ CONTINUATION

☐ DIVISIONAL

☐ FILED "A"
(Old "R")

OTHER _____

ATTORNEY: Jian Zhou

DATE: July 3, 2001

* WITH BASLE FAX (On U.S. Originated Case Only)

F19



DATE: July 25, 2001

Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556
Our Ref.

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880A/CGV2112
Application No.: 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☒ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)


Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,


Jian Zhou
678-415-4691

Filed 5.10.02
Docket Note / Report Entry

Case No.: CUV-30880/A/6V212 Application No.: 09/525,158

Present Docket Date: June 5 / 2002

☐ Extend To: / /

F20

The Following Action Has Been Taken:

- | | | | |
|---|---------------------------------|--|---------------------------------|
| <input type="checkbox"/> Amendment / Response | | <input type="checkbox"/> Issue Fee | \$1280 |
| <input type="checkbox"/> Appeal Brief | \$320 | <input type="checkbox"/> Notice of Appeal | \$320 |
| <input type="checkbox"/> Assignment Recordation | \$40 | <input type="checkbox"/> Preliminary Amendment | |
| <input type="checkbox"/> Application Data Sheet | | <input type="checkbox"/> PTO - 1449 Form | |
| <input type="checkbox"/> Claim of Priority | | <input type="checkbox"/> Request for Certificate of Correction | |
| <input type="checkbox"/> Declaration - Missing Parts / | \$130 | <input type="checkbox"/> Request for Corrected Filing Receipt | |
| Missing Requirements | | <input type="checkbox"/> Response to Final Rejection | |
| <input type="checkbox"/> Disclosure No. <u> </u> | | <input type="checkbox"/> Supplemental Information | |
| <input type="checkbox"/> Division Check | | Disclosure Statement | |
| <input type="checkbox"/> Drawings | | <input type="checkbox"/> Late Fee (\$180) | <input type="checkbox"/> No Fee |
| <input type="checkbox"/> Information Disclosure Statement | | | |
| <input type="checkbox"/> Late Fee (\$180) | <input type="checkbox"/> No Fee | | |

☐ **Extensions of Time**

☐ 1st (\$110) ☐ 2nd (\$400) ☐ 3rd (\$920)

- | | | |
|--|--|-------|
| <input type="checkbox"/> Application (With Basle Fax -- on U.S.
Originated Case Only) | <input type="checkbox"/> Provisional | \$160 |
| <input type="checkbox"/> PCT | <input type="checkbox"/> Petition to Convert | \$50 |

Fee \$ ☐ CIP ☐ Continuation ☐ Divisional ☐ Filed "A" (Old "R")

X Other Petition to Withdraw HOLDING OF ABANDONMENT

ATTORNEY: Bian Zhong DATE: 5, 10, 02
(SUC)

UNITED STATES PATENT & TRADEMARK OFFICE
Washington, D.C. 20231

REQUEST FOR PATENT FEE REFUND				
1 Date of Request: 11/06/08		2 Serial/Patent # 09/525,158		
3 Please refund the following fee(s):		4 PAPER NUMBER	5 DATE FILED	6 AMOUNT
	Filing			\$
	Amendment			\$
	Extension of Time			\$
	Notice of Appeal/Appeal			\$
X	Petition 1453	16	06/25/08	\$ 1,540.00
	Issue			\$
	Cert of Correction/Terminal Disc.			\$
	Maintenance			\$
	Assignment			\$
	Other			\$
		7 TOTAL AMOUNT OF REFUND		\$ 1,540.00
		8 TO BE REFUNDED BY:		
10 REASON:			Treasury Check	
	Overpayment	X	Credit Deposit A/C #:	
X	Duplicate Payment		9 5 0 -- 2 9 6 5	
	No Fee Due (Explanation):			
fee was paid with initial petition 9/14/07				
11 REFUND REQUESTED BY:				
TYPED/PRINTED NAME: Douglas I. Wood		TITLE: Senior Petitions Attorney		
SIGNATURE: /douglas wood/		PHONE: 571-272-3231		
OFFICE: Office of Petitions				
***** THIS SPACE RESERVED FOR FINANCE USE ONLY: *****				
APPROVED: <i>Chlorok</i>		DATE: 11/12/08		

Instructions for completion of this form appear on the back. After completion, attach white and yellow copies to the official file and mail or hand-carry to:

**Office of Finance
Refund Branch
Crystal Park One, Room 802B**

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.